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Abstract
The human immunodeficiency virus type 1 (HIV-1) protease (PR) is a 
critical drug target as it is responsible for virion maturation. Mutations within the 
active site (1°) of the PR directly interfere with inhibitor binding while mutations 
distal to the active site (2°) to restore enzymatic fitness. Increasing mutation 
number is not directly proportional to the severity of resistance, suggesting that 
resistance is not simply additive but that it is interdependent. The 
interdependency of both primary and secondary mutations to drive protease 
inhibitor (PI) resistance is grossly understudied. 
To structurally and dynamically characterize the direct role of secondary 
mutations in drug resistance, I selected a panel of single-site mutant protease 
crystal structures complexed with the PI darunavir (DRV). From these studies, I 
developed a network hypothesis that explains how mutations outside the active 
site are able to perpetuate changes to the active site of the protease to disrupt 
inhibitor binding.
I then expanded the panel to include highly mutated multi-drug resistant 
variants.  To elucidate the interdependency between primary and secondary 
mutations I used statistical and machine-learning techniques to determine which 
specific mutations underlie the perturbations of key inter-molecular interactions. 
From these studies, I have determined that mutations distal to the active site are 
able to perturb the global PR hydrogen bonding patterns, while primary and 
secondary mutations cooperatively perturb hydrophobic contacts between the PR 
and DRV. Discerning and exploiting the mechanisms that underlie drug 
viii
resistance in viral targets could proactively ameliorate both current treatment and 
inhibitor design for HIV-1 targets.
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1Chapter I Introduction
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1.1 HIV-1 history and life cycle 
1.1.1 History of HIV-1
In 1981 the CDC published in their Morbidity and Mortality Weekly Report 
(MMWR) about a group of five young, previously healthy, homosexual men that 
had undergone biopsy were confirmed to have Pneumocystis carinii pneumonia 
(PCP) at three different hospitals in Los Angeles, California [1].  Before the report 
was published, two of the men had already expired. Although the CDC did not 
know at the time that this group of five men had succumbed to what we now 
know as acquired immune deficiency syndrome (AIDS), this report was the 
beginning of the collaborative efforts to identify AIDS and determine its causative 
agent HIV. Shortly after issuing this report, the CDC was overwhelmed with more 
instances of both PCP and a rare aggressive cancer known as Kaposi’s sarcoma 
(KS) from both New York and California [2].  
The following year, in 1982, the CDC published in MMWR an update on 
AIDS, which became the first official use of the term [3]. It would however, take 
another two years to identify the viral etiology of AIDS.  The hunt for the human 
immunodeficiency virus started with several false leads. Because AIDS infection 
appeared to be a chronic disease marked by a long lag time between exposure 
and immune suppression and manifested itself by secondary infections and 
cancers in the clinic, there were many factors from fungi to chemicals that were 
considered as possible causes. However, for the scientists at the National 
Institutes of Health (NIH) in Bethesda, MD and at the Pasteur Institute in Paris, 
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France there were many clues. These included the decreased levels of CD4 T-
cells, the ability of the virus to be transmitted through blood, sexual activity and 
from mother to infant. Cases being reported in hemophiliacs left scientists 
searching for what they thought was a human T-cell leukemia virus (HTLV) and 
possibly related to HTLV-II.  There were even several early publications in Nature 
and Science that reported the complete sequence and gene expression for 
HTLV-III and AIDS-Associated Retrovirus (ARV-2) [4, 5].  
That the causative agent of AIDS was a retrovirus like HTLV was correct, 
but the assumption that the virus was a relative of HTLV proved to be incorrect. 
Sequencing and cloning of an AIDS-causing virus isolate from a patient with 
lymphadenopathy at the Pasteur Institute helped shift the hunt from HTLV to 
what was then known as the lymphodenopathy AIDS virus (LAV) because it too 
was a retrovirus but was not evolutionarily similar to HTLV I or II [6, 7].  With 
subsequent studies, including the ability to grow the virus in T-Cell lines, human 
immunodeficiency virus (HIV) was accepted as the causative agent for AIDS in 
1984 and it was given a formal name in 1986 [8, 9]. 
Once the linkage between HIV and AIDS was determined, the search for 
its origin began. Very early on François Clavel and coworkers were able to 
isolate a new human retrovirus from West African AIDS patients that was more 
similar to simian T-Cell lymphotrophic virus in macaques (STLV-IIImac) than it was 
to the AIDS-related virus reported in America [10]. Because the new STLV-IIImac 
like virus was similar to LAV with the exception of some differences in the 
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envelope glycoproteins, Clavel and coworkers referred to this virus as LAV-II, 
which is what we now know as HIV-2. Continued work led to findings that STLV-
III was in fact simian immunodeficiency virus (SIV), a lentivirus causing chronic 
and persistent infection in mammals similar to its relative HIV with differing 
antigenicity, and ability to induce a disease similar to human AIDS [11, 12].  Like 
HIV, SIV too can be transmitted through sexual intercourse and mother to child 
transmission. SIV was originally thought to not impact its natural host, but it was 
later discovered that primate communities impacted by SIV had higher immune 
system suppression and mortality rates than those that were not infected [13-15]. 
One SIV in particular is genetically closer to HIV-1 than the rest and that is 
SIV from chimpanzees (SIVcpz).  Morever, the human evolved HIV-1 can be 
specifically traced back to the Pan troglodytes troglodytes (P.t. troglodytes) 
subspecies of chimpanzee. Although HIV-1 could be traced back to 
chimpanzees, the origin of SIVcpz remained a mystery until characterization of 
its genome revealed that not only was it closely related to SIV found in red 
capped mangabeys (SIVrcm). It was also derived from non-human 
primatesrelated to red-capped mangabeys (other monkeys from the 
Cercopithecus species)[16]. These findings suggested that there was cross-
species transmission from smaller monkeys to chimpanzees possibly due to 
chimpanzees’ hunting behavior[17].  SIVcpz also had cross-species infection into 
gorillas but the origin of this has yet to be discovered. Both SIVcpz and SIVgor 
5
have been identified as reservoirs for human HIV, possibly due to human 
bushmeat hunting [18, 19]. 
In recent years findings show that HIV-1 can be broken further into four 
different lineages also known as groups. In order of discovery and prevalence, 
there is the main group M, followed by groups N, O (outlier) and P [20, 21]. 
Group M also represents the pandemic form of HIV-1 and has been traced back 
to Kinshasa in the Democratic Republic of Congo [12, 22].  HIV-1 group M can 
be further broken into nine subtypes known as clades (A-D, F-H, J & K) [23] and 
due to recombination in people already infected with one subtype, there are also 
over 40 circulating recombinant forms (CRFs) [24].  Subtype B accounts for the 
majority of HIV-1 group M infections in Europe and the Americas and viral 
sequencing studies indicate that this specific subtype left Africa and moved 
onward to Haiti then to the United States [25]. 
1.1.2  The HIV-1 viral life cycle
The HIV-1 genome encodes nine open reading frames, three of which 
contain the gag, pol and env polyprotein common to all retroviruses (Figure 1.1). 
Nef
MA CA p2 NC p1 p6
PR RT IN
Vif
Vpu SU
TM
vpu
Tat
Rev
Rev
Tat
5’LTR 3’LTR
Gag
Pol Env
Figure 1.1 The HIV-1 genome. The Gag, Pol, and Env polyproteins are labeled 
accordingly with individual proteins shown separated by white bars. 
Accessory proteins and 5’ and 3’ LTR  are labeled accordingly. 
6There are four proteins encoded within the gag precursor polyprotein, matrix 
(MA), capsid (CA), nucleocapsid (NC), and p6. There are three proteins encoded 
within the pol region of the gag-pol precursor polyprotein, protease (PR), reverse 
transcriptase (RT), and integrase (IN).  There are two proteins encoded in the 
envelope precursor polyprotein, the surface protein (SU, gp120) and the 
transmembrane protein (TM, gp41). The gag and envelope proteins make up the 
structural components of the viral particle while the enzymes within the pol 
polyprotein provide essential functions necessary to create fully infectious viral 
particles. There are also six other proteins contained within the virus known as 
accessory proteins, which undertake various tasks to ensure that viral replication 
succeeds. These are Vif, Vpr, Nef, Tat, Rev and Vpu. 
The viral genome itself is encoded by two copies of a 9kb positive sense 
RNA that gets packaged into the virion with the help of zinc finger containing NC 
protein.  The myristolation site at the N-terminus of MA allows anchoring to the 
plasma membrane of the host cell along with the rest of the full-length gag-pro-
pol polypeptide precursor. The capsid proteins, once cleaved from the 
aforementioned precursor, form a conical shaped structure at the center of the 
virus that encapsulates the RNA and NC proteins. p6 contains binding domains 
for viral protein Vpr as well as host proteins from the endosomal sorting 
complexes required for transport (ESCRT) pathway [26]. The viral envelope 
proteins are targeted to the cell membrane after cleavage by the cellular 
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protease furin into gp120 and gp41, after being co-translationally inserted in the 
endoplasmic reticulum (ER) membrane and travelling through the host cells 
secretory pathway via vesicular transport. 
Both accessory proteins Nef and Vpu play a role in down-regulating CD4 
with Nef working to down-regulate CD4 at the cell surface via endocytosis and 
Vpu working to down-regulate CD4 in the ER. Both Nef and Vpu also antagonize 
host proteins such as tetherin [17, 27]. Rev binds the rev response element 
(RRE) and is required to transport the unspliced viral mRNAs from the cell 
nucleus to the cell cytoplasm, which would otherwise be retained in the nucleus 
and degraded. Tat is required to bind to the trans-activating response element or 
TAR in order to promote transcription. Finally, the protein Vpr is important for 
nuclear localization in general but it is specifically responsible for facilitating 
transport of nucleoprotein complexes and partially reverse transcribed DNA into 
the host cell nucleus [27]. 
For entry into a host cell, the envelope protein gp120 binds to host cell 
receptor CD4. This binding event leads to a conformational change in the viral 
envelope protein, which allows it to then expose gp41. gp41 binds to a co-
receptor, either CXCR4 or CCR5, for entry. The viral membrane and the host 
membrane then fuse, which allows the entry of components within the viral 
particle into the cell. At some point during entry, the viral capsid uncoats to 
release the viral RNA and proteins into the cell cytoplasm where the RNA is 
subsequently reverse transcribed by the RT into a duplex linear DNA and 
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transferred to the cell nucleus by Vpr. Inside the nucleus, integrase performs a 
series of steps to integrate the viral DNA into the host cell genome. Viral 
transcripts are then expressed using Tat to enhance binding to the promoter in 
the 5’ LTR to enhance transcription initiation. The newly transcribed viral mRNAs 
are then transferred from the nucleus to the cytoplasm mostly unspliced by Rev 
where they are subsequently translated and targeted to various locations in the 
cell.  As the viral particles assemble at the cell membrane, the viral protease is 
activated and is able to cleave itself out of the polyprotein, dimerize, then cleave 
other proteins to ensure that the viral particle is mature and infectious. 
All necessary viral components and a lysyl tRNA from the host cell are 
used to prime the cDNA are packaged into the budding virion.  Although the HIV-
1 Gag polyprotein is largely able to mediate the events necessary for viral 
budding at the plasma membrane, it is the recruitment and binding of host 
proteins Tsg101 and ALIX from the ESCRT pathway to p6 that drive the 
membrane fission between virion and host cell (Figure 1.3) [28-31]. Once the 
process is complete, the virion moves on to infect another CD4+ T-cell. This 
process can be seen in Figure 1.2.
9Figure 1.2 The HIV-1 viral life-cycle [32].
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Figure 1.3 ESCRT machinery used for membrane fission in HIV-1 budding [26]. 
Auxiliary factors are shown in parentheses. The p6 (protein) region within 
Gag contains two different late domain motifs, the primary domanin consists 
of residues Pro-Tyr-Ala-Pro (“PTAP”) and binds the TSG101 subunit of 
heterotetrameric ESCRT-1 complex (red, and complexed with ubiquitin 
black). The secondary “YPXL”(Tyr-Pro-X=variable-Leu) domain binds the 
ESCRT factor ALIX (blue). These interactions recruit ESCRT-III (made of CHMP 
1, 2 and 4, green) which polymerize into a dome and promotes closure of the 
membrane neck and VPS4 ATP-ases(purple) which uses the energy from ATP 
to release ESCRT-III back into the cytoplasm.
1.1.3 HIV heterogeneity and in vivo evolution
Simply put, the human immunodeficiency virus is a replication machine. 
HIV-1 is able to evolve at a rate several orders of magnitude faster than host T-
cells, taking just ~2 days to produce an entirely new generation of viral particles 
on the order of 1010 virions per day [33-36]. The secret weapon behind this mass 
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viral production is the RT. RT is naturally error-prone due to its lack of a 
proofreading mechanism, the virus can replicate without interruption even though 
the consequence of this replication is 3-4 x10-5 mutations per base per cycle. 
That is, the RT introduces a mutation every 1000-10,000 nucleotides [37-39].  
Because the HIV-1 genome is only 9-10 kb, the rate of mutation ranges from 1 to 
10 per genome for every replication cycle. 
The high mutation rate caused by RT’s lack of proof-reading is only one 
means by which the virus is able to substantiate genetic diversity while 
replicating within its host. Due to its ability to produce genetically distinct yet 
highly related viruses, HIV-1 is said to be a quasispecies [40]. Because HIV-1 is 
a quasispecies, an infected patient may contain a population of viruses with high 
variation of genetic information [41-44].  HIV-1 is also able to recombine with 
other subtypes of virus replicating within the same cell [24, 45]. Recombination 
can occur at one or more steps during viral replication. For instance, since there 
are two copies of RNA packaged into each virion the RT is able to switch 
between the RNAs, promoting strand transfer, and because there are no 
checkpoints for the virus as there are for the host cell, the RNAs that get packed 
into a budding virion can contain information from two different viral sequences. 
By default, recombination can also occur during repair of any damage done to 
either of the viral RNAs [46]. There has even been evidence of viral 
recombination between two major groups, M and O [47].  The inherent genetic 
12
diversity within the virus allows multiple pathways for viral adaptation and poses 
a challenge to HIV-1 chemotherapy.
1.1.4 HIV-1 and the immune system
In the midst of early HIV-1 discoveries in the 1980s and 1990s, there was 
one more observation that was not well understood: exactly how did HIV-1 cause 
CD4+ T-cell depletion in infected patients? At first, there were reports that HIV-1 
did in fact cause T-cell depletion. Ho and coworkers showed that prior to any 
chemotherapies, continuous rounds of HIV-1 infection caused the turnover of ~ 
2x109 CD4+ T-cells per day [35, 48]. How this turnover was driven was unclear. 
The lack of a well-defined answer to these questions led to many theories such 
as, HIV-1 was somehow able to alter the natural homing response of CD4+ and 
CD8+ T-cells out of lymphoid tissue and into circulation upon the presentation of 
antigen such that there would be more T-cells for HIV-1 to infect and destroy [49-
51].  Another theory stated that uninfected T-cells activated for immune response 
would be infected by HIV-1 and not replenished due to thymic depletion [52, 53]. 
Finally, another theory stated that HIV-1 was able to suppress hematopoiesis 
[54]. 
It was not until relatively recently that Warner C. Greene and colleagues at 
the Gladstone Institute of Virology and Immunology established the cause of 
death for CD4+ T-cells as a result of HIV infection.  In both instances, the groups 
stated that CD4 T-cells die via mechanistic caspase-1 mediated pyropoptosis 
and not the canonical caspase-3 mediated apoptosis [55]. This group previously 
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published that only 5% of CD4s are productively infected (the virus is able to 
integrate and replicate fully) and circulating in the blood while 95% of the CD4+ 
T-cells within the lymphoid tissue are abortively infected (the virus cannot 
integrate and replicate resulting in abortive transcripts in the cytoplasm)[56]. This 
“by-stander” population in the lymphoid tissue however is most affected by HIV-1 
infection. Greene and co-workers found that cell death of the circulating 
population of T-cells that produce productively infective virus is triggered through 
caspase-1 mediated apoptosis. However, when HIV-1 abortively infects 
nonpermissive CD4 T-cells cell death occurs by caspase-3 mediated 
pyropoptosis, which accounts for the majority of cell death within the lymphoid 
tissue [57, 58]. Because HIV-1 causes pathogenic inflammation, the signals 
between cells to promote clearance are disrupted and instead of clearing the 
infection, more cells are attracted to infected tissue and meet the same fate as 
resident CD4 T-cells, which in turn causes more inflammation and the cycle 
continues. 
The above scenario precisely underscores why antiretrovirals (ARVs) are 
vital to HIV-1 suppression: replication must be halted to disrupt the infection 
cycle. Because ARVs suppress viral replication by inhibiting entry, reverse 
transcription, integration and polyprotein cleavage, they subsequently prevent the 
above processes from occurring and in turn allow for the continued proliferation 
of T-cells in the presence on infection. ARVs are subsequently able to block the 
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host response by preventing viral replication and genetic diversity to overcome 
the lack of proper host response.
1.2 The HIV-1 Protease 
1.2.1 HIV-1 protease structure and function
HIV-1 is a retrovirus with the same basic composition as other 
retroviruses; a gag gene encoding structural proteins, a pol gene encoding 
enzymes necessary for replication and an env gene encoding proteins for viral 
entry. HIV-1 is slightly different than other retroviruses in that it also encodes for 
several proteins unique only to the virus [59]. Of the proteins common to all 
retroviruses, HIV-1 contains a protease encoded within the pol gene used by the 
virus to cleave peptide bonds between various proteins within the precursor 
polyproteins of the virus and even some within the host that interfere with viral 
replication or necessary to induce cell death [55, 60, 61].  
The HIV-1 protease, or retropepsin as classified within the enyme 
classification system (E.C. 3.4.23.16), is a hydrolase. More specifically, it is an 
aspartic endopeptidase related to cathepsin D, renin and human endogenous 
retrovirus K10 protease [62, 63]. As with all eukaryotic aspartic proteases, HIV-1 
protease contains two catalytic aspartic acids within its active site necessary for 
the enzyme to function. Early structural and expression and purification studies 
confirmed that HIV-1 protease functions as a dimer, with each monomer 
contributing one aspartate to the active site [64, 65]. In addition to the HIV-1 
protease’s catalytic dyad each monomer contributes a threonine and a glycine in 
15
the order Asp25-Thr26-Gly27, which are necessary for protein dimerization as the 
two monomers are not covalently linked [66]. The protease contains two flaps, 
one from each monomer, which open and close to allow substrates into the 
active site cleft (Figure 1.4) [67]. Studies showed that the HIV-1 protease was 
highly specific with respect to the cleavage sites within its substrates [68]. 
However, due to the diversity of residues surrounding the scissile bond, 
questions remain as to why or how the protease performed hydrolysis on these 
specific sites.
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Figure 1.4 Open, partially open and closed conformations of HIV-1 protease. N 
and C termini are colored in green and red respectively. “A and B” monomers 
are colored in blue and cyan to differentiate.  Conformations in A & B were 
originally described in [69] accession codes 3UHL and 3UF3. Conformation in 
C was originally described in [70] accession code 1T3R.
17
Of the twelve substrates within the virus that undergo cleavage by the protease, 
the majority of them contain a small hydrophobic residue at the P1 position while 
the residue on the other side of the scissile bond at the P1’ site is generally a 
proline but it often varies. It would not be until twenty years later that the 
determinant of the specificity of the protease was elucidated. 
Like all other hydrolases the HIV-1 protease catalyzes the 
hydrolysis of peptide bonds in the form;
𝐴 ‒ 𝐵 + 𝐻2𝑂 →𝐴 ‒ 𝑂𝐻 + 𝐵 ‒ 𝐻
where A−B represents the peptide bond between two amino acids. The widely 
accepted mechanism behind this reaction is as follows; the two aspartic acid 
residues within the active site begin a water mediated attack on a nearby 
nucleophilic hydroxyl group from the backbone of a residue.  Due to the pH 
dependent reaction of the protease, the nucleophilic attack begins from the 
aspartic acid residue that is not protonated. The water that is attacked by the 
unprotonated Asp subsequently attacks the carbonyl carbon, which allows for 
release of the oxygen of the carbonyl group. This forms an unstable tetrahedral 
intermediate where the originally protonated Asp residue is intermediately 
hydrogen bonded to the substrate. Subsequent protonation of the nitrogen from 
the amide group of the original peptide bond and rearrangement causes the 
tetrahedral intermediate to breakdown and hydrolysis succeeds (Figure 1.5) [71].  
Understanding and exploiting the mechanism of action used by the protease to 
18
hydrolyze substrates has proven to be incomparably vital to treatment of 
individuals with HIV-1 via inhibiting the protease. 
Figure 1.5 HIV-1 protease mechanism of action [72].
1.2.2 The HIV-1 protease as a drug target
Soon after the discovery that HIV-1 protease was in fact an aspartyl 
protease that functioned as a dimer, it was identified as a potential target for 
therapeutics after an experiment showed that inhibition via a frame shift mutation 
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resulted in the failure of the protease to process the gag polypeptide [73]. With 
this information, the search began for molecules capable of inhibiting the 
protease. Naturally, given that the HIV-1 protease was an aspartyl protease, 
some researchers tried to use known inhibitors of other aspartic proteases on the 
HIV-1 protease such as various forms of pepstatin and renin inhibitors [74]. 
 Although these general aspartic protease inhibitors proved not to be 
effective on HIV-1 protease, the rationale taken from preliminary studies, that 
HIV-1 protease inhibitors should transition state mimics, proved to be vital in the 
years and trials to come. A focus on improving the non-hydrolyzable 
hydroxyethylene isosteres was undertaken by many groups since this was the 
preliminary scaffold for pepstatin inhibitors [75, 76]. With new structural 
information and armed with the knowledge that HIV-1 protease had the unique 
ability to cleave between sites containing phenylalanine/tyrosine and proline 
residues—which are not susceptible to cleavage by mammalian endopetidases— 
creating mimics of these residues around the pepstatin-based scaffolds proved 
successful. However, what proved to be even more successful was the use of a 
hydroxyethylamine isostere scaffold instead of the reduced amide scaffold to 
better serve as a mimetic of the Phe-Pro and Tyr-Pro scissile bonds [77]. The 
use of large hydrophobic side chain mimics served to fill the subsites within the 
protease, which played into the protease’s elusive specificity. The hydroxyl based 
scaffolds (e.g. hydroxyethylene, -ethylamine,  or –ethylamino sulfonamides) were 
more potent against the HIV-1 protease because the presence of the hydroxyl 
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group displaced the active site water and engaged both Asp residues into a 
transition state like interaction.  Compounds made using this scaffolding were 
also found to be highly specific to targeting the protease, which in turn reduced 
toxicity and mistargeting of host aspartyl proteases. These notable 
advancements in protease inhibitor design are arguably the start of rational 
structure-based drug design.
Using the techniques and chemical scaffolds mentioned above, the first 
protease inhibitor, saquinavir (Fortovase™/Invirase™), was approved as a 
protease inhibitor by the FDA in 1995 followed by ritonavir (Norvir™) in 1996.  
Prior to this, there was only the reverse transcriptase inhibitor azidothymidine 
(AZT/ Zidovudine, ZDV™) approved in 1986. The protease is active late in viral 
maturation and its ability to process substrates is crucial for maturation and 
infectivity of newly budding virions. Treatment with protease inhibitors prevents 
the necessary cleavage events from occurring thereby rendering virus particle 
incapable of infecting another cell (schematic Figure 1.6). This feature had given 
protease inhibitors a unique advantage over the likes of AZT, which halts viral 
replication in newly infected cells, as protease inhibitors are also able to disrupt 
virus generated from chronically infected cells. As an RT inhibitor, AZT is only 
able to inhibit it’s target in acutely infected cells [78].
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Figure 1.6 Schematic diagram of HIV-1 protease inhibition [79].
1.3 History of HIV-1 treatment and generations of protease 
inhibitors
1.3.1 The progression of antiretroviral treatment from monotherapies 
toward a vaccine
Dr. Anthony Fauci of the National Institutes of Health (NIH, Bethesda, MD) 
accurately categorized the treatment history of HIV-1 treatment into three 
phases: the “dark ages” from 1981–1986, the “pre-highly active antiretroviral 
therapy (HAART) era from 1987–1996, and the “HAART” era from 1996–
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2006[80]. Certainly, at the discovery of AIDS in 1981 scientists were far behind in 
piecing together the puzzle of the relation of HIV and AIDS but once HIV was 
found to be a retrovirus, the work of finding inhibitors to slow viral replication 
began. As mentioned previously, researchers started with known aspartic acid 
protease inhibitors and soon found that these were ineffective. Initially, HIV-1 
therapy constituted of AZT monotherapy-which was approved by the FDA in a 
record 21 months, followed by a series of other nucleoside reverse transcriptase 
inhibitors (NRTIs) including didanosine (ddI, Videx™) in 1991, 3TC(Lamivudine, 
Epivir™) in 1995.
With information gained from protease/inhibitor co-crystal complex 
structures, the commencement of protease inhibitor (PI) design was initiated [81-
83].  Concurrent with clinical development of PIs was the refinement of intra-host 
HIV-1 quantitation assays. These new methods for determining the amount of 
virus within an individual were based on viral RNA copy number within the 
plasma instead of CD4 count, and were thereby more sensitive to both viral load 
and viral inhibition [33, 35, 84, 85]. Although highly potent in vitro, early protease 
inhibitors had low bioavailability, which means that patients had to inject 
themselves in order for the drug to be administered. With some refinement of 
solubility, the bioavailability of protease inhibitors improved, allowing patients the 
ability to take them orally [86]. 
The issue of viral heterogeneity proved highly problematic in the very early 
stages of HIV therapeutics. Because there is simply not one single viral strain 
23
within a host, many groups sought to figure out how to quantitatively account for 
this in inhibitor design [87-89]. The viral propensity to mutate and recombine in 
addition to the short term effective inhibition of early monotherapies called for re-
evaluation of how to best administer antiretrovirals to effectively inhibit all pre-
existing mutant populations [90]. The interpretation of several mathematical 
models and experimental findings concluded that at least two or more drugs 
should be given to patients to help both with longer lasting and more effective 
antiretroviral treatment better suited to ward off the rise of mutations and drug 
resistance. Initial combination therapy consisted of the administration of NRTIs 
such as AZT and 3TC which in time ultimately led to failure after a slightly 
extended period of time when compared to monotherapies with either drug [91, 
92]. 
It was not until the introduction of PIs to therapeutic regimens either as 
additional monotherapeutics or in combination with failing regimens (i.e. 2 NRTIs 
+1 PI) that HAART was born [93]. Over time, the types of combinations have 
increased with the number of approved inhibitors. Because of the potency, 
propensity to slow viral progression and lack of other interfering parameters (low 
bioavailabity, high toxicity etc.) the combination of 2 NRTIs + 1 PI has become 
the standard for HIV-1 treatment in naïve patients [94]. There have also been 
many studies conducted with PIs in combination with other PIs and with non-
NRTIs (NNRTIs) however these have proven to be less optimal except in 
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instances where ritonavir is used as a “booster” (cytochrome P-450 inhibitor) to 
increase the half-life of other protease inhibitors. 
The advancement of HIV-1 chemotherapy over the past few decades has 
been met with many challenges and setbacks but has progressed to be highly 
effective and has prolonged the life expectancy of those living with the virus. 
Because HAART is typically a life-long treatment and cannot cure individuals, 
there have been strides made to find an HIV-1 vaccine to prevent and eradicate 
the virus once and for all. However, like the early days of drug discovery for the 
virus, the hunt for a vaccine is met with challenges. In recent years, major effort 
has been devoted to T-cell vaccine trials with moderate success. One of the 
major setbacks to vaccine trials has been the lack of ability to generate broadly 
neutralizing antibodies (BNAbs) due to HIV-1  eliciting only a limited response 
from these kinds of antibodies years after initial infection [95-97]. The fact that 
the virus can go years being undetected by the immune system with respect to 
antibody response is a major problem in and of itself due the virus’ archetypical 
ability to establish heterogeneity. Thus, in order to produce an effective vaccine, 
we must first understand how to enhance antibody response [98].
1.3.2 Outcomes of Prolonged Treatment and Aging with HIV
For the 34 million people living with HIV-1 today, the efficacy of 
combinatorial antiretroviral therapy is essentially allowing individuals to live full 
lives. However, with prolonged survival come challenges to the typical aging 
process. Some of these challenges include the onset of comorbidities at an 
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earlier age than in non-infected individuals (diabetes, heart disease, kidney 
disease, etc.). As previously mentioned, antiretroviral therapy is life long and this 
means that some individuals will be exposed to therapy for many decades. With 
this prolonged exposure, the chances of toxicity are increased due to change in 
physiological conditions of the human body with age. Because of this, there may 
be need to work towards new inhibitors that are more tolerable, have lowered 
interactions with drugs taken for other age related morbidities, or that are longer 
lasting and thereby taken less frequently [99]. 
With age too, comes the contraction of the thymus, the organ responsible 
for T-cell development. As the thymus shrinks due to age, it also produces less 
naïve T-cells. The increased levels of T-cells within infected individuals with HIV 
is a hallmark of treatment, however, the loss of T-cells or their function can cause 
HIV to progress more rapidly in the elderly. There is also the problem of 
neurocognitive abnormalities, such as AIDS related dementia in the elderly living 
with HIV.  Simply put, the increased life expectancy for those infected with HIV 
comes at a cost. The natural aging defects seen in HIV negative individuals are 
compounded in those afflicted with the disease. This means that antiretroviral 
therapy should not be the last stop in HIV treatment, but instead should be the 
first step of many to ensure that HIV remains controllable and tolerable 
throughout the life of the afflicted. 
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1.3.3 Non-adherence to antiretrovirals leads to resistance
Several clinical studies have made the connection clear: adherence to 
antiretroviral regimens is the key to continued viral suppression. Adherence to 
treatment regimens even reduces the opportunistic infections such as PCP [100]. 
Combination therapy is the most effective means by which doctors can help 
patients keep their viremia low, so low in fact that with adherence viral levels can 
be suppressed below detection levels. The reason why HAART is so effective at 
viral suppression lies in the fact that using a combination of drugs decreases the 
probability of selecting a viral population that is resistant to all the drugs in one 
regimen. However, there are several factors that sometimes make regimen 
adherence difficult for patients. These include intolerance to one or more of the 
drugs within the cocktail, lack of access to therapy, high baseline viral loads, or 
poor pharmacokinetics of ARVs [101-103]. Although deviating from prescribed 
treatment regimens or discontinuing treatment altogether is not advised, some 
patients choose not to adhere to therapy and this in turn leads to viral resistance. 
Selection of drug resistant viral populations due to lack of chemotherapy 
undermines the efficacy of ARVs and subsequently leads patients on a path to 
complete ARV failure via viral rebound [103-105]. 
As mentioned previously, the addition of protease inhibitors significantly 
increases the efficacy of ARV regimens, even for patients failing on NRTI or 
NNRTI based regimens, due to their very high viral suppression activity [78].  
Amazingly, it has been shown in several clinical trials that regimens containing a 
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PI in addition to some combination of other viral enzyme inhibitors do not select 
for protease mutations [103, 106, 107]. Instead mutations at targets of other 
drugs within the regimen are more prevalent[108]. Although in theory this is how 
HAART should work, even with mutations against two of three drugs, it is not 
understood why failure occurs in the presence of a protease inhibitor if there are 
no mutations within the protease itself [106-109].  In a 2012 modeling study, 
David Rosenbloom and coworkers developed a mathematical model to predict 
how long after the last treatment dose (before non-adherence) would the virus 
(either mutant or WT) begin to rebound. This study they found that the level of 
adherence needed avoid viral rebound is dependent upon the class of drug. For 
instance, patients on NNRTIs should adhere to their regimens as much as 
possible beacause of an increased risk of mutant viral growth while patients on a 
boosted protease inhibitor regimen have a bit more room for non-adherence due 
to wildtype viral regrowth. This result consistent with clinical findings that patients 
on NNRTI and PI therapy typically encounter virological failure [86]. They also 
found, specifically for protease inhibitors, that the sharp dose-response curve 
and rapid decay of PI concentrations leaves little room for mutant population 
growth in a period of non-adherence. This suggests that patients who fail 
protease inhibitor therapy should be able to re-suppress their virus with improved 
adherence [110]. 
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1.3.4 Improvement on protease inhibitors with each generation 
To date there are nine FDA approved competitive HIV-1 protease 
inhibitors, eight of which are peptidomimetics based on the early transition state 
mimic conceptual foundation in the 1980s [111]. The inhibitors can be broken into 
generations depending on their time of discovery and approval. The first 
generation inhibitors saquinavir (SQV), ritonavir (RTV), indinavir (IDV), nelfinavir 
(NFV) and amprenavir (APV) are largely not prescribed anymore. The second 
generation inhibitors lopinavir (LPV), atazanavir (ATV), tipranavir (non-
peptidomimetic, TPV), and darunavir (DRV) are largely still in clinical use with 
boosted LPV or ATV being among the most prescribed PIs in antiretroviral 
regimens. The majority of these approved inhibitors share strong chemical 
commonalities; for instance, the second generation LPV was largely based on 
the chemical scaffold of RTV, while APV and DRV differ by just the addition of a 
tetrahydrofuran group to the latter. Although the protease inhibitors as a class are 
highly potent against their target, side effects that they may cause make them 
very intolerable to some patients. For instance TPV, it is only to be prescribed at 
absolute failure of other PIs due to its hepatotoxicity and its necessity to be 
double boosted by RTV. Only recently has DRV been approved to be given as a 
first line PI in chemotherapy regimens. 
Protease inhibitors essentially inactivate the enzyme by binding at the 
active site and locking the flaps down, mimicking prolonged transition state. To 
overcome this inhibition, the protease develops mutations that prevent the 
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inhibitors from binding. However, the accumulation of mutations typically comes 
at a cost; the enzyme loses the efficiency of processing natural substrates, also 
known as fitness. To aid in fitness recovery, the virus also develops additional 
mutations within either within the protease or elsewhere within Gag and Gag-Pro-
Pol polypeptide, which improve cleavage of substrates, known as substrate co-
evolution [112]. Studies have shown that not only do the mutations within and 
surrounding cleavage sites improve enzymatic fitness, they are also able, in 
conjunction with the protease, to help drive resistance to PIs [113, 114]. In fact, in 
a study by Parry et al, the non-peptidomimetic TPV was the only PI assayed that 
both a mutant protease and mutant Gag remained susceptible to even though 
TPV interacts with the protease in a similar way as the other PIs [115]. In any 
case, resistance to all nine FDA-approved inhibitors has been documented and 
mutations that underlie PI resistance never appear alone. Some of the 
resistance-causing mutations within the protease directly confer resistance to PIs 
while others arise to restore viral fitness loss via the presence of mutations that 
are detrimental to substrate turnover. 
1.3.5 The role of structure based drug design in creating more effective PIs
With the precedent set in the late 1980s and the early 1990s, rational 
structure based drug design (SBDD) has become the superior technique in the 
conquest to combat HIV-1. Although, in the case of HIV-1, use of rational drug 
design was a means to an end race against time, it has advanced to become 
ends to a mean tool in the field of pharmacology, with entire companies built on 
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this foundation [116].  The process now, iterative but certainly more robust, 
typically involves expression/purification, structural determination of the target to 
be inhibited, identification of possible inhibitors followed by biochemical assays to 
determine potency, and structure determination of a target-inhibitor complex to 
unveil molecular interactions that can possibly be enhanced to improve potency 
[117]. 
With respect to rational drug design of antiretrovirals against HIV-1, there 
is no question that the design of protease inhibitors has triumphed over other 
target inhibitors. It was pure serendipity that led to the discovery of Enfuvirtide™, 
the first HIV-1 inhibitor of gp41 preventing fusion and small molecule screening 
that led to the discovery of its counterpart maraviroc which inhibits gp120 from 
binding to the CCR5 co-receptor [118, 119]. Specifically for the enzymes 
encoded within the pol gene, the initial administration of AZT was given to 
patients without the structure of RT or RT in complex with an inhibitor being 
known [120]. And while integrase’s structure was elucidated in 1994, the first 
integrase inhibitor, raltegravir (RAL), was approved in 2008 with some chemical 
based intuition and some true to form rational design. Still with the advancement 
of such parameters as computational power, small molecule screening, and 
crystallographic screening automation, inhibitors of the HIV-1 protease remain 
the unsurpassed prototypes for structure based rational design. 
The mechanistic approaches used in conjunction with SBDD have further 
been improved upon. For instance, Lee and coworkers have found success using 
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a solvent anchoring approach utilizing a covalently attached phosphonate moiety 
to increase the potency of inhibitors while others such as Tidor and coworkers 
have found success using inverse design methods utilizing the substrate volume 
as a restraint to dictate inhibitor design [121, 122]. The most successful 
mechanistic approach in the past decade appears to be maximizing the 
interactions between the enzyme and the inhibitor, such as that used by Mitsuya 
and coworkers [123]. With this strategy, the most potent FDA approved HIV-1 
protease inhibitor to date, darunavir (DRV/Prezista™) has been discovered.  
While both fairly recently approved PIs darunavir and tipranavir(TPV/Aptivus™) 
are highly potent against the protease and highly resistant variants, DRV has 
better bioavailability and slightly lower levels of toxicity. By targeting the 
backbone atoms of residues in the protease’s active site, Mitsuya and coworkers 
unlocked a key facet lacking in previously approved inhibitors. That DRV is able 
to form many hydrogen bonds with the backbone atoms of the protease allows it 
to overcome drug resistance in a manner that is different than that of TPV, which 
directly interacts with the flaps of the protease.
1.4 Drug resistance to ARVs
1.4.1 Why drug resistance occurs in HIV-1
HIV-1 is masterfully erroneous. With high levels of productivity and the 
inherently inaccurate nature of the very enzyme responsible for transcribing its 
genome, drug resistance in HIV-1 is a matter of eventuality par for the course.  
With its implicit heterogeneity, ARVs are essentially able to target the most 
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susceptible quasispecies within the host. However, with the targeting and 
subsequent downfall of one viral population comes the uprising of a population 
that is resistant to the antiviral agents administered. Though it is not a simple 
process, if the population containing the appropriate mutation(s) is prevalent 
enough, it can provide a selective advantage to the virus in the form of 
resistance. There is also the issue of cross-resistance within those targets for 
which there are multiple inhibitors. Cross-resistance occurs when a mutation 
selected for by one inhibitor is inherently resistant to another inhibitor from the 
same class. If combination therapy is given and works effectively then viral 
replication is suppressed; however, if for any reason the ARVs are not as 
effective and the virus is allowed to replicate in the presence of these drugs then 
it is quite possible that the drug may posses the ability to apply selective 
pressure to the target warranting a mutation. And once viral resistance occurs, it 
is almost impossible to control expansion of the viral population [124].
Within each target, signature mutations develop in response to exposure 
to the antiviral agent used. For example, the M184V mutation lies in the heart of 
the RT active site and arises in response to targeting by NRTIs. This change 
from methionine to valine disallows the incorporation of  thymidine analog 
inhibitors and thereby disabling chain termination [125]. Because NNRTIs bind 
directly to the RT, they are able to block the flexibility of the enzyme and its ability 
to synthesize DNA; consequently, the residues within this binding site mutate to 
overcome this targeting [126]. Resistance to entry inhibitors such as enfuvirtide 
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occurs through the development of mutations in hydrophobic region 1 (HR1) 
within gp41 that allow for the continued rearrangement of gp41 and its fusion to 
the host cell via restored communication between HR1 and HR2 [127]. Integrase, 
being a highly complex multi-domain enzyme, develops resistance via multiple 
pathways. Perhaps the most well studied is resistance to RAL, which involves 
mutations at Q148 and N155 within the catalytic core domain (CCD) that restore 
the coordination of metals by the active site Asp residues blocked by integrase 
inhibitors [128, 129]. 
1.4.2 Drug resistance in the HIV-1 protease
Resistance to HIV-1 protease inhibitors is multi-faceted, involving 
mutations within the and outside the active site of the enzyme as well as at 
protease cleavage sites. Like other targets for which there are multiple drugs 
within the same class, the protease is also able to develop cross-resistance to 
multiple PIs, with some mutations in the active site conferring resistance to all PIs 
such as mutations at V82 of I84 [130].  Because inhibitors are conformationally 
constrained and make highly specific interactions with active site residues, they 
exhibit high affinity for the wild-type target but cannot accommodate changes due 
to mutations unlike substrates or inhibitors that are less constrained [131]. 
Molecular mechanisms of PI resistance consist of reduced interactions with the 
inhibitor, shifting of backbone atoms due to mutation, alterations of the dimer 
interface, transmission of changes perpetuated from outside of the active site 
and mutations that cause a more relaxed transition state intermediate [132]. 
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With so many non-homologous cleavage sites, the mystery underlying 
how the protease is not only able to recognize its cleavage sites but also how it is 
still able to process these substrates despite a vast array of accumulated 
mutations has only been elucidated in recent years. First came the discovery that 
the protease’s molecular recognition is not in fact guided by amino acid 
sequence but instead but instead a conserved shape or volume that overlapping 
substrates occupy when bound at the active site, termed the substrate 
envelope[133].  
The finding of the substrate envelope provided understanding for how 
some mutations within the protease are detrimental to inhibitor binding but do not 
affect substrate turnover. The comparison of overlapping of the inhibitors — 
termed the inhibitor envelope—to the substrate envelope revealed that the 
inhibitors occupy a certain volume within the active site but also protrude outside 
the substrate envelope [134]. The sites at which the inhibitors protruded beyond 
the substrate envelope corresponded to amino acid sites where mutations to 
inhibitors generally arise. PIs are smaller than natural substrates for 
bioavailability purposes with shapes different than that of the substrates but 
containing similar moieties. Because of their size and tendency to fit similarly 
within the subsites of the enzyme, it was clear that multiple inhibitors could select  
for the same mutation, thereby causing cross-resistance.
 To overcome resistance or otherwise shift the balance between substrate 
recognition and drug targeting in favor of the latter, it is advantageous that an 
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inhibitor is able to fit within the substrate envelope. In this case the inhibitor 
should retain maximum potency despite mutations, as with DRV, which was not 
designed with the substrate envelope fit as a constraint but does fit well within 
the envelope. DRV is described as having a high genetic barrier to resistance, 
which means that multiple mutations within and outside of the active site need to 
accumulate to confer resistance to DRV [135]. Still, even with this knowledge, the 
issue of how high levels of accumulated mutations within the protease work 
together to drive drug resistance to even the most potent of inhibitors remains 
elusive.  
1.5 The importance of understanding the role of mutations in PI 
resistance
1.5.1 The role of active site mutations within the protease
No sooner than the first protease inhibitors were developed and 
administered in clinical trials did the problem of resistance in patients become 
apparent [136]. Protease inhibitors represent a large class of drugs in ARV 
therapy, and a larger number of mutations are selected against PIs than other 
ARV classes. Furthermore, each inhibitor selects for its very own set of primary 
(major) mutations—those that directly interfere with inhibitor binding—and 
secondary (minor) mutations—those that do not directly interfere with inhibitor 
binding.  For example, resistance to the first FDA approved inhibitor SQV was 
driven by mutations G48V and L90M, while RTV selects for mutations at 82, 54, 
71 and 36 [137]. Over the years there have been extensive research efforts to 
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elucidate key mutations in conferring resistance to protease inhibitors. With the 
improvements in SBDD, more effort has been put forth to predict how a specific 
mutation may impact inhibitor binding as the inhibitor is designed. The increased 
level of cross-resistance between PIs has made this objective increasingly 
necessary.  Predicting the order and patterns with which mutations occur still 
remains a formidable challenge even with the knowledge of the mutations 
selected by different PIs. 
The protease’s active site is comprised of the catalytic residues D25, T26 
& G27 along with several other residues including R8, L23, A28, D29, D30, V32, 
K45, M46, I47, G48, G49, I50, T80, P81, V82 & I84 [132].  All nine FDA-
approved PIs select for a mutation of at least one, if not more, of these residues. 
Because these mutations make up the active site, their role in substrate turnover 
is crucial. Changes at any of these sites not only interfere with inhibitor binding 
but also with substrate turnover. For instance, the mutation I50V is a major 
mutation affecting DRV binding while I50L is a major mutation in resistance to 
ATV, and neither inhibitor is a match for the flexibility and adaptability allowed by 
the co-evolved substrate [138, 139]. 
It should be noted that active site mutations impair enzymatic fitness in the 
absence of drug. However, in the presence of drug in some cases mutations 
within the active site render the virus as fit or even more fit than the initial wild-
type population. Active site mutations often get outcompeted by mutations that 
do not cause considerable fitness impairment in the absence of drug [140]. Still, 
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the virus has to find a balance so that it is dually able to carry out its biological 
function while not being effectively inhibited, and the most readily identifiable 
ways to achieve this balance is to develop mutations distal to the active site to 
compensate for any fitness loss endured due to primary mutations. 
1.5.2 The role of distal mutations in enzyme fitness compensation
Whether PIs selected for their resistance specific major mutations or 
mutations within the active site, one observation was made clear very early on; 
those mutations never developed alone. In addition, those major or active site 
mutations that did arise alone were eventually outcompeted by viral populations 
containing a combination of major resistance mutations and minor secondary 
mutations. Some studies early on made the effort of tracking the ordered 
accumulation of mutations in the protease and in a very precise manner, the 
protease developed mutations within the active site first and then further 
developed several minor mutations outside of the active site [137]. More 
experimental studies showed that after a certain point the additions of more 
mutations no longer aided in replicative fitness but began to hamper the 
enzyme’s replicative capacity in the presence of drug [141]. 
Some studies specifically looked at the enzymatic fitness of protease with 
mutations developed against an inhibitor that selects for them, while others 
sought to determine if fitness could be restored by mutations not selected for by 
a specific inhibitor in the absence of drug [140].  There are even some studies 
that give secondary mutations a larger role in viral replication by examining their 
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ability to increase virulence and the progression of disease in the absence of 
therapy [142, 143].  In this regard, strides have been made to predict the 
evolution and individual fitness scores of these distal mutations over the course 
of treatment, which showed that patients that accumulated many secondary 
mutations had higher fitness scores, which equaled higher viral loads, and lower 
CD4 counts [144].  For secondary mutations, the theories all center around one 
focus; compensatory mutations have the sole purpose of increasing enzymatic 
fitness to perpetuate viral replication and disease progression. While the role of 
secondary mutations in this faction of viral replication has been more or less 
proven, the role in drug resistance in the absence of primary mutations- remains 
grossly understudied
1.5.3  The role of distal mutations in drug resistance 
As mentioned above, protease variants that are able to remain resistant to 
inhibitors while retaining biological function tend to harbor a number of secondary 
mutations. Many reports have shown through crystallographic or enzyme kinetics 
studies that secondary mutations may aid in drug resistance via widening the 
active site, expanding the substrate envelope itself, and changing the 
conformation of the flaps from closed to partially open [69, 145-147]. 
Interestingly, proteases that contain many secondary mutations generally only 
contain 1-2 active site mutations. Several questions regarding secondary 
mutations arise that have yet to be fully addressed: Why does the protease 
accumulate so many non-active site mutations? How do these mutations 
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communicate changes to the active site and flap regions of the protease? Are 
there overlapping patterns used by distal mutations to circumvent inhibitor 
binding?
There have been studies, though few and far in between, that examine the 
role of secondary mutations in the presence of active site mutations [148, 149]. 
Despite supporting evidence of distal mutations being able to drive, albeit low 
levels of, resistance in the form of reduced binding energies and in the absence 
of active site mutations, very little has been done to decompose the 
interdependency of mutations beyond the active site alone, collectively, and in 
conjunction with active site mutations [150-153]. There are a number of studies 
on distal mutations individually or in pairs, there have been only a limited number 
of attempts to elucidate the roles of secondary mutations in larger (>10), highly 
complex combinations of mutations [154-156]. 
Although there has been a recent surge of studies on clinically derived 
isolates trying to decipher the role of distal mutations in complex combinations, 
the issue of elucidating how these mutations work together interdependently 
remains a mystery. Acquiring a high number of mutations does not directly 
correlate with resistance suggesting that the effect of mutations in conferring 
resistance is not additive. For this reason there must be significant effort put forth 
to gain a complete understanding of resistance in terms of how mutations in 
small or large mutational contexts are able to drive resistance. Elucidating the 
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roles of distal mutations in drug resistance may be the key to finally preventing 
failure of ARV therapy.
1.5.4 Possible mechanisms used by non-active site mutations to propagate 
changes to the active site and flaps of the protease
Our laboratory has previously found that 19 residues outside of the HIV-1 
protease active site lie within a highly hydrophobic region, or the hydrophobic 
core, and conformational dynamic changes involving these residues are 
intimately linked to flap opening and protease function [157]. The residues within 
this core facilitate conformational changes via the sliding of residues past one 
another with minimal energetic expense, termed hydrophobic sliding. Many of the 
residues within this core region are associated with drug resistance and are 
thought to alter the conformational flexibility of the protease, which subsequently 
impact the binding of inhibitor or substrate. Our laboratory has also confirmed 
that restricting these core residues undergoing hydrophobic sliding resulted in a 
dramatic loss of function. [158].  Given their roles in protein flexibility and 
function, studies such as these have laid the groundwork for elucidating the roles 
of distal mutations in drug resistance.
The examination of distal mutations dynamically has proven to be very 
insightful.  Molecular dynamics studies allow for the following of details that 
cannot readily be seen experimentally or crystallographically.  Through molecular 
dynamics simulations, Mittal et al were able to see just how much enzyme 
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flexibility was reduced when residues within the hydrophobic core were 
engineered in affixed positions, causing reduction in enzymatic function [158]. It 
is with dynamics that Appadurai et al were able to ascertain that protease distal 
mutations cause the active site to become uncoupled with the flaps causing a 
loss of contacts with the inhibitor [153]. 
1.5.5 Secondary mutations and drug resistance in non-protease targets
The HIV-1 protease is not the only target that makes use of secondary 
mutations to drive resistance. Secondary mutations pose a threat to resistance 
for many disease targets within and outside of HIV-1. The HIV-1 integrase, 
whose first inhibitor has been approved within this decade, develops secondary 
mutations to circumvent inhibitor binding. A study by Nakahara et al. found that 
primary mutations in the integrase enzyme Q148K or Q148R reduced the 
efficiency by which integrase was able to incorporate viral DNA and that this loss 
of function was restored upon the addition of secondary mutations E138K or 
G140S. They also found that the combination of G140S and Q148R was able to 
drive a greater and 6 fold increase in resistance to one of the compounds tested 
[159]. Because of the increased fold change in resistance and the ability to 
restore viral replication and infectivity, they deduced that the combinations of 
primary and secondary mutations within the integrase evolved due to the specific 
abilities that the presence of the secondary mutations could restore. 
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Beyond HIV-1, anti-cancer therapies are thwarted by the development of 
drug resistance. A well-studied example is the epidermal growth factor receptor 
(EGFR) family of receptor tyrosine kinases (RTKs), which stimulates non-small 
cell lung cancer (NSCLC). This transmembrane protein is activated upon binding 
ligands like EGF, which in turn causes the homodimerization of two EGFRs and 
the autophosphorylation of the TK domain and downstream cell signaling. 
However, the signaling events initiated by EGFR can be dysregulated due to 
activating mutations within the TK domain. Although some activating mutations 
make the TK domain more sensitive to the inhibitors gefitinib and erlotinib, there 
are some that cause the TK domain to remain in a constitutively activated state 
and become resistant to inhibitors. To overcome the hypersusceptibility of some 
activating mutations, EGFR develops a secondary mutation T790M, which is 
important for regulating inhibitor specificity and increasing affinity for ATP within 
the binding pocket of EGFR allowing ATP to outcompete the inhibitors [160, 161]. 
More cancer-based examples include secondary mutations within BRCA1 
and BRCA2 in breast cancer that allow functions to be restored in BRCA1/2 
mediated tumors along with resistance to inhibitors, and secondary mutations in 
FLT-3 in acute myeloid leukemia. Given that secondary mutations in any drug 
resistant target may primarily work in the same manner, there is a need to 
develop methods to combat resistance caused by both primary and secondary 
mutations. One interesting methodology being explored in improvement of 
cancer therapy is potentiating EGFR for degradation. Another general strategy 
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would be developing inhibitors that would work better against targets with both 
types of mutations, and specifically for cancer targets, developing inhibitors that 
work in targets downstream in signaling pathways while simultaneously inhibiting 
EGFR. 
1.6 The importance of protein dynamics in drug binding and 
resistance
1.6.1 Visualizing protein dynamics to understand resistance
To truly and completely understand how a protein functions, one must be 
able to probe both structural and dynamic properties.  X-ray crystallography has 
been invaluable to visualizing, understanding and targeting with small molecules 
of many proteins. Crystallography has even been able to capture some dynamic 
movements of the HIV-1 protease at high resolution [69, 135]. Still, a great deal 
of information is missed by crystallography in that only a snapshot of the protein 
or biomolecule movement within the crystal lattice can be captured. Because of 
this limitation, methods that allow for the study of protein dynamics have 
enhanced our acumen of molecular recognition. There are both experimental and 
computational methods used to study protein dynamics, including using X-ray 
crystallography in a time resolved manner [162]. Other experimental methods to 
study protein dynamics include nuclear magnetic resonance (NMR), electron 
paramagnetic resonance (EPR), and hydrogen-deuterium exchange [163-165].  
 Although these experimental methods offer the ability to monitor protein 
dynamics, probing dynamics computationally via molecular dynamics (MD) 
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simulations allows for the most highly detailed visualization. When used in 
combination, experiments and MD simulations complement each other in a 
manner by which most researchers can expound upon structural changes 
relevant for function. For example, the 150-loop in influenza neuraminidase 
contains the catalytic residue D151 and is highly flexible. The 150-loop is so 
flexible in some strains that it is not ordered in the crystal lattice and hence 
cannot be seen in x-ray crystal structures. However, Bush and coworkers found 
that the 150-loop can be stabilized by a salt-bridge through use of 
crystallography and MD simulations thereby making this site a possible target for 
inhibitors [166]. 
While all the methods mentioned above have their limitations, the method 
chosen may depend on several factors that are important to the experimentalist. 
For instance, the time scale for which one wishes to run the experiment, the size 
of the macromolecule and properties of the system set in place during the 
experiments should all be taken into consideration prior to choosing a method. 
With advancements in computation (the advent of GPUs and computing 
clusters), increased power of synchrotrons and the automation of several 
methodologies have catapulted these methods into a territory where there are 
very few limitations remaining. 
1.6.2 The role of dynamics in HIV-1 protease resistance
The early structural studies on HIV-1 protease provided a foundation for 
HIV-1 treatment today; however, what no one could glean from the structures of 
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the protease was its flexibility and just how this flexibility, or lack thereof, 
modulates activity. In the decades since those initial structural studies, 
technology has brought the HIV-1 treatment field a long way by allowing for 
increased insight into protein dynamics. From gaining the now straightforward 
knowledge that the proteases movement is not of the simple garden-variety 
hedge shear to the ability to understand the plasticity with which substrates are 
cleaved, it is clear that protein dynamics have catapulted our understanding of 
this small but mighty enzyme. 
The protease flap region is highly flexible with intricate workings designed to 
retain this feature in the absence and presence of mutations [157]. Studies have 
shown that while both wild-type and mutant protease variants are highly flexible 
in the absence of inhibitor, the presence of mutations increases this flexibility 
extensively within the flaps [167]. The protease’s flexibility is not limited to its 
unbound form; it remains flexible even when bound to ligand as well [168-170].  
As mentioned previously, the presence of mutations causes the flaps and active 
site of the protease to become uncoupled, resulting in a loss of contacts 
specifically to the inhibitor. It is with the understanding of both static and dynamic 
alterations afforded by mutations within the protease that we will be able to 
further elucidate the interdependencies of the mechanisms underlying drug 
resistance. 
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1.6.3 The use of computational methods to probe dynamics in relation to 
resistance
The use of MD simulations to aid in structure based drug design and 
general visualization of small molecule dynamics is ever increasing. For instance, 
just this year Nagasundaram and co-workers were able to identify several anti-
malarial compounds that may be able to combat resistance via virtual screening 
and MD simulations [171].  However, the use of MD simulations alone may only 
be able to provide finite detailed information about conformational changes that 
may regulate drug resistance. Although there are copious amounts of information 
that can be determined from resultant MD trajectories, it is up to the user to 
identify which interactions may be key in understanding drug resistant 
mechanisms used by their target. 
In the case of HIV-1 protease, there is a wealth of knowledge pertaining to 
drug resistance including which mutations arise to which inhibitors, which 
mutations underlie cross-resistance and that there is no direct correlation with the 
number of mutations to the severity of resistance. We have been able to identify 
which interactions play a key role in inhibitor binding and have tried to take 
advantage of these interactions and improve upon them [172]. This approach 
does seem a bit retroactive in that there are still no defined mechanisms of 
resistance used by distal mutations to drive drug resistance. Some studies have 
used machine learning techniques and algorithms to predict genotypic and 
phenotypic resistance from large datasets [173]. However, we have learned with 
HIV-1 protease one simple rule of thumb: resistance begets resistance and if 
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viral suppression does not occur, this cycle will continue.  The simple prediction 
of resistance to better shuffle ARVs for a more effective regimen will eventually 
lead to yet another shuffling in a matter of time.  In addition to trying to improve 
inhibitors, we must try to decompose the interdependency employed by distal 
mutations to propagate changes to the active site of the enzyme. Identifying and 
tracking key interactions between a drug resistant protease or a set of proteases 
throughout the duration of MD simulations may only be the first steps on the road 
to unlocking drug resistant mechanisms used by mutations outside of the active. 
Going a step further and using machine learning and statistical techniques to 
parse through any patterns used by mutations may prove to be the pivotal in 
understanding drug resistance from an omniscient perspective.
1.7 I.VII.  Thesis Scope
This thesis attempts to fill the gaps surrounding the role of mutations distal 
to the active site in drug resistance of the HIV-1 protease. Moreover, this thesis 
tries to elucidate the interdependent mechanisms employed by distal mutations 
to drive resistance to the highly potent protease inhibitor darunavir and how the 
elucidation and exploitation of these interdependent mechanisms can proactively 
meliorate both current treatment and inhibitor design for targets within and 
outside of HIV-1. 
First I demonstrate that mutations outside of the active site are able to 
drive resistance independently of active site or other distal mutations using 
information from static and dynamic structural studies of a small panel of 
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protease variants. I also identify and probe key inter-molecular interactions that 
are manipulated by the presence of distal mutations to alter the dynamic 
ensemble of mutant protease-inhibitor complexes (Chapter II). 
I then expand the panel of protease variants to include clinically-derived 
multi-drug resistant (MDR) variants that contain many distal mutations in complex 
combinations. I monitor the key interactions I identified previously via MD 
simulations in these highly mutated proteases. I present that, with the use of 
unsupervised machine learning and statistical techniques, mutations outside of 
the active site are able to operate interdependently to drive resistance to the 
protease inhibitor darunavir (Chapter III). 
How RNA may be able to enhance the catalytic efficiency of MDR 
proteases and the significance of these findings with respect to inhibitor binding 
in non HIV-1 targets will be discussed in Chapter IV. 
49
Chapter II  
Drug Resistance Conferred by Mutations Outside the 
Active Site Through Alterations in the Dynamic and 
Structural Ensemble of HIV-1 Protease
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2.1  Abstract 
HIV-1 protease inhibitors are part of the highly active anti-retroviral therapy 
effectively used in the treatment of HIV infection and AIDS. Darunavir (DRV) is 
the most potent of these inhibitors, soliciting drug resistance only when a 
complex combination of mutations occur both inside and outside the protease 
active site. The role of mutations outside the active site in conferring resistance 
remains elusive. Through a series of DRV–protease complex crystal structures, 
inhibition assays, and molecular dynamics simulations we find that single and 
double site mutations outside the active site often associated with DRV 
resistance alter the structure and dynamic ensemble of HIV-1 protease active 
site. These alterations correlate with the observed inhibitor binding affinities for 
the mutants, and suggest a network hypothesis on how the effect of distal 
mutations are propagated to pivotal residues at the active site and may 
contribute to conferring drug resistance. 
2.2  Introduction
In the absence of a vaccine and in lieu of a cure, antiretroviral combination 
therapy has been the main form of treatment for individuals infected with HIV. As 
is the case with treatment of most rapidly evolving viruses/diseases, drug 
resistance decreases the effectiveness of treatment. The high replicative 
capacity of HIV and the infidelity of the reverse transcriptase quickly lead to a 
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heterogeneous population of viruses within patients, from which resistance has 
emerged to all 30 of the currently used anti-viral drugs.   
HIV-1 protease inhibitors (PIs) have recently emerged as the most 
effective drugs in the treatment of HIV [174-176]. PIs are competitive active site 
inhibitors that mimic the transition state of the enzyme and are the most potent 
antiretroviral drugs for the treatment of HIV/AIDS [110]. These drugs are ideal for 
therapy as they target the viral protease responsible for viral maturation and thus 
the spread of the virus. Unfortunately, the rapid evolution of HIV-1, coupled with 
the selective pressure of therapy, results in many viable multidrug resistant 
variants. In fact mutations at 45 of the 99 residues that make up HIV-1 protease 
have been implicated in drug resistance [177]. While resistance due to mutations 
at 11 of these 45 residues can be explained as direct changes within the active 
site, the resistance mechanisms for the remaining mutations outside the active 
site of the enzyme mostly remain elusive.
Drug resistance mutations in HIV-1 protease allow the enzyme to become 
less susceptible to inhibition while retaining enzymatic activity. Points of inhibitor–
protease contact at residues within the active site where the inhibitor protrudes 
beyond the substrate envelope are sites selected for resistance, as their 
interactions are more critical for inhibitor binding than substrate turnover[134]. 
While mutations at some active site residues, such as 82 and 84, lead to 
resistance to all PIs, other mutations are signatures of specific inhibitors, such as 
D30N for nelfinavir and I47A for lopinavir [178]. These mutations directly impact 
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inhibitor binding by altering or reducing contacts necessary for inhibiting the 
enzyme, but can also simultaneously decrease the catalytic efficiency or 
enzymatic fitness. The mutations at the remaining 34 of the 45 residues 
associated with drug resistance occur outside the active site. These changes 
have often been considered secondary or accessory mutations, and are thought 
to indirectly impact inhibitor binding while assisting in enzyme fitness or stability. 
Structural studies on the effect of several HIV-1 protease secondary mutations 
have provided insights into how inhibitor binding may be affected [156, 157, 179-
181]. However for the most part, their specific role in protease inhibitor resistance 
or mechanism of action has not been elucidated. 
Darunavir (DRV) is the most potent of the FDA approved HIV-1 protease 
inhibitors. This high potency combined with the inhibitor’s fit within the substrate 
envelope appears to account for DRV’s robustness against drug resistance[182, 
183]. Drug resistance to DRV usually occurs only in patients who have high 
levels of pre-existing PI resistance, requiring at least seven mutations to 
simultaneously occur for therapeutic failure. In fact, DRV is being investigated as 
a potential mono-therapy in treatment-naïve patients [184]. 
In DRV-resistant HIV variants, many changes occur outside the active site 
of the enzyme in complex combinations. Single site mutations cannot confer high 
levels of resistance to DRV, and a combination of multiple mutations including 
those outside the active site are needed to decrease potency.  However the role 
of these mutations in conferring resistance is not well understood: some may be 
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enhancing enzymatic activity, while others may directly confer drug resistance 
and still others may be residual mutations from previous therapy history.  In this 
study, we examine some of the most common of these mutations—V32I, L33F, 
L76V, and L90M (as a control; not a signature of DRV resistance but frequent in 
multidrug resistance [180]—for their impact on DRV inhibition. Using a 
combination of static and dynamic structural analyses, by determining crystal 
structures of complexes and performing molecular dynamics simulations, we 
elucidate the possible roles of these secondary mutations both independently 
(L76V, L90M, V32I) and in combination (V32I/L33F) in conferring resistance. We 
find how mutations at residues with no direct contact with the inhibitor can alter 
the structure and dynamics of the protease to affect inhibitor binding through 
common mechanisms, which we define through a “network hypothesis”. 
2.3  Results
To determine how mutations remote from the active site contribute to DRV 
resistance in HIV-1 protease, the impact of four mutations (L76V, L90M, V32I, 
and V32I/L33F; Figure 2.1) in a subtype B background was investigated in terms 
of enzyme inhibition, inhibitor-bound crystal structures, and molecular dynamics 
simulations. 
2.3.1 Enzyme Inhibition
The enzyme inhibition constant for DRV was measured against each of 
the protease mutants, in addition to WT subtypes B and C for comparison (Table 
2.1). DRV is highly potent against WT subtype B protease with a Ki of 2 pM, as 
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we previously reported [182]. The level of inhibition for the mutants varied from 2 
pM to 45 pM, with the L90M mutant being inhibited as potently as the WT 
protease and the V32I/L33F double mutant exhibiting the greatest decrease in 
susceptibility to DRV with a fold-change greater than 20. Hence, single mutations 
are not enough to confer high levels of DRV resistance, as expected, and the 
mutations had varying degrees of effects on DRV susceptibility. 
Figure 2.1 Structure of HIV-1 protease variants bound to DRV. Crystal 
structures of mutant protease variants superimposed with the WT protease 
complex structure in blue. The side chains od mutation sites are in red sticks.
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Table 2.1 DRV interaction and susceptibility of HIV-1 protease variants. DRV 
inhibition constants (Ki) of HIV-1 protease variants, with fold changes relative 
to subtype B WT protease in parentheses. The overall vdW interaction energy 
between inhibitor and protease was determined from crystal structures.
2.3.2 Crystal Structures
To structurally characterize the effects of the mutations on DRV binding, 
we determined the crystal structures of variants L76V, L90M, V32I, and 
V32I/L33F, which diffracted to resolutions of 1.5–1.9 Å in the P212121 space 
group (Table 2.2). Alignment of the four complex structures on our previously 
determined structure of the WT protease–DRV complex (1T3R [70]) showed that 
the variants had only minor backbone variations, mainly in the 20s loop likely due 
to crystal packing differences (Figure 2.1). Therefore, the mutations had very little 
impact on the overall backbone structure of the protease. 
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Table 2.2 Crystallographic statistics for DRV-Bound HIV-1 protease structures. 
a denotes structure used from [70].
2.3.3 Detailed Structural Analysis of DRV Binding from Co-crystal 
Structures
The high-resolution co-crystal structures enabled detailed analysis of 
protease–DRV contacts in each of the five complexes. The WT complex had the 
most extensive van der Waals (vdW) contacts with the inhibitor with a favorable 
energy of –44.5 kcal/mol, similar to V32I and L90M variants (Table 2.1). The 
L76V variant and V32I/L33F double mutant lost more than 1 kcal/mol in vdW 
contact energy with DRV relative to the WT complex. Thus despite no large-scale 
changes in the protease backbone, subtle changes in repacking occurred around 
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DRV in these two complexes to weaken protease interactions with the inhibitor. 
However, the extent of contacts lost with DRV in the mutant crystal structures 
with respect to WT protease does not correlate completely with the fold-change 
loses in Ki values (Table 2.1).
Contacts involving specific DRV moieties (Figure 2.2) and protease active 
site residues (Figure. 2.3) were analyzed in detail. In general, the impact of 
mutations on DRV contacts are larger at the P2 and P2' than the central P1 and 
P1' moieties. The bis-THF group of DRV P2 moiety forms the most extensive 
contacts in all of the complexes (Figure 2.2), but also loses considerable contacts 
due to the mutations, except in the V32I structure. In the case of V32I, DRV 
contacts are retained as in the WT complex, consistent with no significant 
change in total vdW or Ki values (Table 2.1). When this mutation occurs together 
with L33F in the double mutant though, contacts are lost in all three of P2, P1 
and P2' moieties. In L90M variant, although interactions get weaker at the P2 
position, gain of contacts at P1 compensate for this loss yielding comparable 
total vdW contacts and susceptibility to DRV as WT protease.
While the apo form of the protease is a symmetric homodimer, DRV 
induces asymmetry to the complex and thus despite identical residues mutating 
in both monomers, the effect of these mutations on protease–inhibitor contacts is 
distinct in the two monomers (Figure 2.3). Specifically, L76V and L90M mutations 
cause considerable loss of contacts at I47, but to a lesser extent at I47'. Other 
active site residues whose contacts are altered in mutant structures include I50 
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at the tip of the flaps, and 81-82-84 at the 80s loop. Contrary to previous [132], 
we do not see any major enhancement of DRV contacts with the catalytic D25 in 
the L90M mutant, or any of the other 3 variants. 
Figure 2.2 Contacts of DRV moieties with HIV-1 protease variants. A. Chemical 
structure of DRV(TMC114) with the inhibitor moieties P2-P2’ indicated. B. 
vdW interaction energy(kcal/mol) of DRV moieties for contacts with the 
protease active site in the crystal structures, and changes in vdW interaction 
energy in mutant structures relative to the WT complex. Positive values 
indicate loss of contacts.
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Residue 32 is at the periphery of the active site, and V32I mutation causes 
a unique pattern of rearrangement of inhibitor contacts than the other variants 
studied. Unlike L76V and L90M, contacts with 47 are retained in V32I. Although 
the backbone is not shifted significantly, the proximity of residue 32 to the 80s 
loop causes subtle rearrangements to result in repositioning of the DRV away 
from I84’s and more towards I50’s at the tip of the flaps. As a result, DRV 
contacts with residues 84, 81' and 84' are lost but those with 50 and 50' are 
enhanced. The larger isoleucine also forms additional contacts with the inhibitor 
in the unprimed-side monomer. In the V32I/L33F variant, which loses an 
additional 7-fold in binding affinity relative to V32I (Table 2.1), the contacts are 
rearranged again. In contrast with V32I alone, additional loss of interactions at 
residues 47 and 50 are observed. These losses of contacts are similar to the 
alterations observed in the L76V and L90M variants. Thus the double mutant 
V32I/L33F variant alters the active site in a synergistic manner, leveraging both 
alterations similar to L76V and L90M, and some changes from V32I. The change 
in variants’ affinity is not simply due to a loss of van der Waals contacts, but an 
interdependent change in optimal contacts. 
In the WT complex, DRV forms a network of hydrogen bonds within the 
active site involving both backbone and side chains. Most of these bonds, 
including the two water-mediated ones with I50, are conserved in the variant 
complexes. Two exceptions occurred in the L76V and V32I complexes: 
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Figure 2.3 Contacts of protease active site residues with DRV in the crystal 
structures. A. The two monomers of WT protease in surface representation 
with the bound DRV displayed as sticks. Active site residues are colored from 
blue to red for increasing vdW contacts with the inhibitor. The monomer that 
interacts mostly with the P2-P1 moieties of  DRV is on the left, and the primed-
side monomer is on the right. B. The vdW interaction energy of active site 
residuesin crystal structures (top), and changes in mutant complexes relative 
to the WT structure (bottom). Only the residues displaying considerable 
changes relative to WT are included for both monomers. See Figure 2.10 for 
information on changes in all active site residues. Positive values indicate loss 
of contacts.
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Consistent with the loss of vdW contacts, in the L76V complex a hydrogen bond 
to the backbone of D30 is lengthened from 2.0 to 3.0 Å. In the V32I variant, an 
additional water-mediated hydrogen bond with the side chain of D30 is formed. 
Nevertheless, overall the hydrogen bonds with DRV within the various complexes 
are conserved.
2.3.4  Dynamic Simulations of Complexes
Analysis of crystal structures above revealed that the mutations away from 
the active site are able to influence interactions of DRV-contacting residues at 
the active site. The alterations in vdW contacts or hydrogen bonds lost, however, 
only partly correlate with the experimentally determined enzyme inhibition 
constants. Another possible mechanism by which these secondary mutations 
could alter inhibitor binding is by influencing the dynamic ensemble of the 
enzyme.
Starting from the crystal structures of the DRV complexes, three replicates 
of fully hydrated 10 ns MD simulations of each DRV complex were performed 
and analyzed. Root-mean-square deviations (RMSD) of Cα atoms during the 
simulation and the average root-mean-square fluctuations (RMSF) about their 
mean positions readily reveal that the secondary mutations alter the overall 
enzyme dynamics (Figure 2.4, Top). The L90M and V32I/L33F variants display 
larger fluctuations throughout the enzyme compared to the other variants, 
although the catalytic D25 stays relatively rigid in both monomers. These altered 
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fluctuations are not restricted to the sites of mutation, but propagate throughout 
the enzyme.
To further analyze the impact of mutations on the dynamic ensemble 
sampled by the protease, the distance distributions were calculated across the 
active site at a variety of positions (Figure 2.4, Bottom and Figure 2.5). In all the 
variant complexes, the dynamic ensemble sampled by the protease is altered 
relative to WT. Many of the distances displaying a significant change are longer 
than the WT distance, indicating a widening of the active site. In the L76V 
complex, the changes are highly asymmetric, with one side of the active site 
constricting and the other widening (Figure 2.4 Bottom). In all variant complexes, 
alterations involve residues in the 80s loops. The 80s loops in both monomers 
form the “side walls” of the active site. Relative to the WT complex, the distance 
between residues 81 in the two monomers are shorter, and that between 84–84′ 
are longer in all variants. Hence, the “upper” part of the side walls are closer and 
the “lower” part is farther away in the mutant complexes compared to the WT. In 
addition to the 80s loop, certain distances involving residue 50 at the tip of the 
flaps, and even the catalytic D25 are altered in the variant complexes. The 
catalytic site is the most invariant and dynamically restricted region of the 
protease, both when different crystal structures are compared and dynamics 
analyzed by simulations and NMR experiments [167, 168, 185]. Therefore, 
widening of the D25–D25′ distance in the V32I/L33F double mutant is an 
unusually profound impact of remote changes on the catalytic region.
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Figure 2.4 Molecular dynamics simulations of DRV-HIV-1 protease complexes. 
Top. RMSD of Cα atoms from the initial positions, and RMS fluctuations of 
residues averaged over three 10ns trajectories. Bottom. Significantly altered 
change in distance between residue pairs around the active site relative to WT 
complex, smapled during the MD simulations; increased and decreased 
distances are indicated by blue and red respectively. 
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Figure 2.5 Sample of distance distributions between residue pairs around the 
active site over three 10ns MD trajectories of DRV-bound HIV-1 protease 
complexes. Distances involving residue 84 shown specifically. 
65
The MD simulations also permitted a detailed analysis of the interaction 
network both for direct interactions within the active site to DRV and the internal 
hydrogen-bonding network throughout the enzyme (Figure 2.6 and Figures 2.7-
9). Throughout the MD simulations the WT complex maintains a network of 
stable hydrogen bonds. Starting from the bottom of the enzyme the c-terminal α-
helix forms a network of hydrogen bonds that links the termini of the protein to 
the flap regions. The backbone of residue 95 links to residue 90 which in turn 
contacts residue 86, residue 88 bridges to residues 29, 31, and 74, and residue 
76 bonds to both residues 31 and 33 which is bonded to residue 78. Residues 29 
and 30 make direct hydrogen bonds to DRV in both monomers. The hydrogen 
bonds linking residues 47 and 54 within the flaps stay tightly hydrogen bonded 
throughout the simulation. Thus, as we previously observed[157], the hydrogen 
bonding network is stably retained within the WT MD simulation.
In comparing the simulations of the variant DRV complexes with the WT, 
subtle changes are seen in the vdW contacts within the active site (Figure 2.9), 
similar to what was observed in the crystal structures. However, in each of the 
four variants, with the notable exception of the 47–54 linkages, the hydrogen 
bond network is disrupted to a greater or lesser extent asymmetrically, including 
the direct hydrogen bonds with DRV (Figure 2.6B and 2.7-8). The V32I/L33F 
variant is the most disrupted with 12 hydrogen bonds changing by greater than 
20% relative to the WT complex throughout the dimer, with 11 being weakened 
(Figure 2.6D) including most dramatically the interactions of the side chain of Asn 
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88. Eight of these changes are within the monomer that coordinates the highly 
rigid bis-THF moiety including weakened interactions at points of contact 
between the protein and DRV. Thus, mutations distal to the active site often 
weaken the strength of the hydrogen bonds in the network, which is propagated 
through to the active site including altering vdW packing, pushing the flaps, and 
thereby the contact of I47 with DRV. Taken together, one can decipher how 
contacts between protein and inhibitor are affected by these changes even for 
residues that are packed through vdW contacts or covalently linked along the 
backbone and are not directly involved in the hydrogen bonding network (Figure 
2.6A and C).
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Figure 2.6 Network of hydrogen bonds within HIV-1 protease. (A) Crystal 
structure of DRV bound to the active site, and only one monomer of the 
protease is shown for clarity. The sites of mutation (L76, L90, V32, and L33) 
have colored side chains. (B) Histograms of the changes of the percentage time 
hydrogen bonds are formed relative to the WT simulation for each of the 
complexes. (C) Schematic hydrogen bond network of the HIV-1 protease dimer 
with the percentage time hydrogen bonds are formed during the WT 
simulation (Figure 2.7). (D) Schematic representation of the V32I_L33F 
complex simulation with the change in hydrogen bonding relative to the WT 
simulations. The remaining variants schematic are shown in Figure 2.8.
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Figure 2.7 Histograms of total hydrogen bond duration as percentage of time 
during MD simulations. Top: Duration between specified residue pairs in the 
monomer binding the P2’moiety of DRV. Bottom: hydrogen bond duration in 
the monomer binding the P2 moiety of DRV
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Figure 2.8 Schematic representation of hydrogen bonding over the course of 
the simulation for L90M, L76V and V32I, percentages are relative to the length 
of time observed for the WT simulation (Fig 2.6 B, C and 2.7).
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Figure 2.9 Histograms of vdW between DRV and protease during MD 
simulations.
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Figure 2.10 Changes in vdW interaction energy (kcal/mol) of active site 
residues with DRV in HIV-1 protease crystal structures relative to the WT 
complex.
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2.4  Discussion
HIV-1 protease evolves in complex combinations to evade inhibition, but 
still maintains biological function. The active site mutations have a relatively 
straightforward mechanism of disturbing the inhibition–function balance, which is 
effectively explained by the substrate envelope[134]. However, in highly resistant 
variants, active site mutations often coexist with mutations outside the active site. 
This is particularly necessary when resistance is achieved to the highly potent 
inhibitor DRV, which fits well within the substrate envelope. However, the role of 
these changes outside the active site has long been thought to be only in 
recovering viral fitness, or protease stability.
In the current study, we have primarily chosen enzyme variants that are 
associated with DRV resistance: L76V, V32I, and L33F[186] Although L76V 
causes only a 1.5-fold decrease in DRV binding affinity (Table 2.1), this mutation 
is often observed in highly mutated DRV-resistant variants[154, 187], as well as 
variants with hyper-susceptibility to other PIs. L33F is a highly networked 
mutation co-occurring with many others in highly drug-resistant patient isolates, 
often together with V32I [188]. Therefore, comparison of V32I and the V32I/L33F 
double mutant permits the context-dependence of mutational effects in drug 
resistance. While not directly associated with DRV resistance, L90M is a 
canonical highly networked mutation that typically arises in multidrug resistant 
proteases. The large and rigid P1/P1′ moieties in NFV and SQV have been 
implicated in susceptibility to L90M, a feature lacking in DRV [180] L90M has 
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been found in more than half of patient isolates with at least one PI resistance 
substitution, and hence is often present in patients needing DRV-based salvage 
therapy [188]. Thus, elucidating the physical impact of these secondary 
mutations on DRV binding provides a detailed perspective on how the enzyme 
accommodates such frequently observed changes.
Specifically, we find that mutations outside the active site impact inhibitor 
binding thereby playing a direct role in conferring drug resistance. Compared to 
the WT complex, the overall structure and backbone conformations are very 
similar in the co-crystal structures of the variant complexes. However, the 
mutations cause subtle but significant rearrangements in the structure to cause 
altered interactions with the bound inhibitor, as well as impacting the dynamic 
ensembles of these complexes. We had previously hypothesized [157] and 
tested [158] that alterations in the hydrophobic core of the enzyme could alter the 
conformational dynamic ensemble through changes in the hydrophobic sliding of 
internal residues potentially impacting drug resistance. This impact on dynamics 
is not localized to the points of mutation but would propagate throughout the 
enzyme. In the present study we hypothesize these mutations outside the active 
site share a common pathway of altering the overall enzyme dynamics and 
propagating their effects to the active site.
Although the resistance-associated mutations are located at a variety of 
positions in the protease and away from the active site, they all may utilize a 
common mechanism or pathway of altering the protease–inhibitor interactions. 
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The mutations cause subtle changes through the repacking of the active site; in 
particular, these are observed in the crystal structures at residues 47, 50, and 84 
in both monomers, and also observed in the MD analysis (Figure 2.9). Within the 
crystal structures of both the L76V and L90M complexes residue I47, which is 
located in the flap, loses contact with DRV. In contrast, in the V32I complex I47 
contacts are retained, while this loss is restored when L33F occurs in V32I/L33F 
(these changes are also observed in subtle differences in the MD 
simulation Figure 2.9). Interestingly, V32I and I47V are the second most frequent 
pair of residues often found to coevolve, thus compensating for each other [188]. 
Mutations at I47, together with I54, which its backbone is hydrogen bonded with, 
is a major DRV resistance site. Among about 30 total active site residues that 
contact DRV, I47 is consistently the residue whose contacts are affected the 
most in L76V, L90M, and V32I/L33F variants (Figure 2.10). These results 
suggest that the interactions of residue 47 with inhibitors within the active site 
may represent a pivotal site in conferring drug resistance to PIs, and these 
interactions can be altered by changes propagated through the enzyme from 
remote sites.
In addition to repacking around the inhibitor in the crystal structures, the 
secondary mutations share a common pattern of altering the dynamic ensemble 
sampled by the protease, and the shape of the active site. Overall in the dynamic 
ensemble of the V32I and the V32I/L33F variants the active site is expanded, 
with the double mutant expanding the active site more, while L76V active site 
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contracts and the L90M active site displays asymmetric changes. Hence, even 
though not located at the active site, mutations at all these remote sites affect the 
shape of the active site in the dynamic ensemble.
How are single mutations at a remote site able to alter interactions and 
dynamics of the active site with highly common molecular mechanisms? We 
propose a “network hypothesis” where the perturbation introduced by mutation of 
a distal residue is propagated to the active site through a network of interactions 
within the protease structure (Figure 2.6). The distal mutation sites we studied 
are all part of a hydrogen-bonded network connecting to the active site where the 
inhibitor binds. Our network hypothesis postulates that the mutations have similar 
effects and common mechanisms as they all cause a rearrangement of this same 
network. This hypothesis is supported by the alterations observed during the MD 
simulations in the stability of the hydrogen bonding networks (Figure 2.6), where 
changes propagate from residues 74–78 and 87–90, through 28–33, to 84–85 
and 25. This altered interaction network includes repacking of the vdW contacts 
with residues 47 and 54, which are pivotal in linking the networked residues to 
the rearrangement of the flaps, residues 29 and 30 that directly hydrogen bond to 
DRV, and 82 and 84 that are key sites within the active site cavity. We 
hypothesize that all these are the active site residues where the impact of distal 
mutations is propagated as a common mechanism of resistance in all variants 
and their subtle rearrangements can cause inhibitor specific resistant changes.
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These common mechanisms provide an explanation for why some 
mutations are redundant and thus are not observed together in patient 
sequences, while others are synergistic and occur together to confer higher 
levels of drug resistance as they impact one another at pivotal sites that confer 
resistance often through expanding the active site. This hypothesis does not 
exclude the possibility that some changes may still provide additional stability, 
increasing the combined fitness of the variants. Most significantly, our findings 
show that all of the mutations we have studied, although outside the active site, 
still directly alter the shape and flexibility of the active site, thus likely play a direct 
role in conferring resistance.
2.5  Methods
2.5.1  Protease Gene Construction
Each of the four protease mutants was constructed using a standard site-
directed mutagenesis protocol on a WT-SF2 protease gene with a codon 
sequence optimized for E. coli expression. The WT PR gene contained the 
amino acid substitution Q7K to minimize the enzyme’s autoproteolytic activity.
2.5.2 Protease Expression and Purification
Each PR mutant was expressed and purified as previously described[189]. 
Briefly, the mutant HIV-1 protease gene was cloned into the pXC-35 plasmid, 
which was then transformed into the TAP56 strain of Escherichia coli. 
Transformed cells were grown in 6 × 1 L cultures from which cell pellets were 
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harvested 3 h after induction. The cell pellets were lysed and the protease was 
retrieved from inclusion bodies with 100% glacial acetic acid. The protease was 
separated from higher molecular weight proteins by size-exclusion 
chromatography on a Sephadex G-75 column. The purified protein was refolded 
by rapid dilution into a 10-fold volume of 0.05 M sodium acetate buffer at pH 5.5, 
containing 10% glycerol, 5% ethylene glycol, and 5 mM dithiothreitol (refolding 
buffer). The protease solution was concentrated, followed by dialysis to remove 
any remaining acetic acid. Protease used for crystallization was further purified 
with a Pharmacia Superdex 75 fast-performance liquid chromatography column 
equilibrated with refolding buffer.
2.5.3 Protease Crystallization
Crystals were set up with a 5-fold molar excess of inhibitor to protease, 
which ensures ubiquitous binding. The final protein concentration ranged from 
0.8 to 1.6 mg/mL in refolding buffer. The hanging-drop method was used for 
crystallization as previously described[189]. For the L76V, L90M, and V32I 
mutants, the reservoir solution consisted of 126 mM phosphate buffer at pH 6.2, 
63 mM sodium citrate, and ammonium sulfate at a range of 24–29%. For the 
V32I/L33F double mutant, the reservoir solution consisted of 0.1 M citrate-
phosphate buffer, 7% DMSO, and 25–30% ammonium sulfate.
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2.5.4 Enzyme Kinetics
Enzyme inhibition studies were carried out using a PerkinElmer Envision 
multilabel plate reader. A substrate peptide mimicking the MA-CA (p17-p24) 
cleavage site labeled with K-E(EDANS)-S-Q-N-Y-P-I-V-Q-K(DABCYL)-R (0.5 
μM, final concentration) was added just prior to the reading to each well 
containing 50 nM of PR and varying concentrations of inhibitor. The FRET pair 
(EDANS, the donor and DABCYL, the quencher) was attached to the indicated 
amino acids of the peptide (Molecular Probes). Fluorescence intensity increase 
upon hydrolysis of the fluorogenic substrate was monitored at 490 nm (emission 
of EDANS) from the highest inhibitor concentration to the lowest, as well as the 
no inhibitor control well. Each inhibitor titration included at least 12 inhibitor 
concentration points. Initial velocities were obtained from the progress curves 
and plotted against inhibitor concentration to get inhibition curves. Resulting 
curves were globally fitted to Morrison’s equation to obtain the Ki value, as 
described previously[190]. 
2.5.5 Evaluation of Hydrogen Bonding and van der Waals interactions
The Maestro component of the Schrödinger software suite was used to 
analyze the hydrogen bonds between the inhibitor and the protease residues and 
neighboring waters after optimization of the complex structure. Briefly, a 
hydrogen bond was defined by a distance between donor and acceptor of <3.5 Å 
and a donor-hydrogen acceptor angle of >120°. The vdW contacts between the 
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inhibitor and protease were calculated using a simplified Lennard–Jones 
potential, following previously published protocols[191].
2.5.6 MD Simulations
The MD simulations were performed using the program Sander in the Amber 8 
package, as previously described[167]. A set of three simulations was run for 
each of the four mutants and the WT-PR yielding a total of 15 trajectories for 
analysis. Each simulation was assigned initial velocities according to the 
Maxwellian distribution and random seeds were assigned with five different 
values for each PR. An in-house script was used to determine the intra and 
intermonomeric Cα distances between various residues using the trajectories. To 
calculate the hydrogen bond duration between various residues within the 
network from the simulations, the Visual Molecular Dynamics (VMD) version 
1.9.1 was used[192, 193]. VMD was used to write out the trajectory in a pdb 
format using the coordinates and trajectory files generated by PTraj from the 
AMBER simulation software. VMD was also used to generate the trajectory pdb 
files to determine the vdW contact energies over the simulations. The in-house 
vdW script was then modified to assess vdW contacts from the simulations. The 
script was run to determine vdW contacts for each of the trajectories. Once the 
robustness of the system was assessed, the three trajectories for each system 
were concatenated into one file containing 1500 frames and the total vdW 
contacts were analyzed [166].
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Chapter III 
Elucidating the Interdependence of Drug Resistance 
from Combinations of Mutations
81
3.1 Abstract
The HIV-1 protease is responsible for the cleavage of 12 non-homologous 
sites within the gag and gag-pro-pol polyproteins in the viral genome. Under the 
selective pressure of inhibition, the protease is able to develop mutations within 
(primary) and outside (secondary) of the active site allowing the protein to 
facilitate substrate processing while simultaneously countering inhibition. The 
primary protease mutations impede inhibitor binding, while the secondary 
mutations are considered accessory mutations that compensate for enzymatic 
fitness loss. However, the role of secondary mutations in conferring drug 
resistance remains a largely unresolved topic. We have shown previously that 
while darunavir is superior to preceding protease inhibitors in viral suppression 
and has a higher barrier to resistance, mutations distal to the active site are able 
to perturb darunavir binding by disruption of the protein’s internal hydrogen-
bonding network [169]. In this study we show that mutations distal to the active 
site can interdependently play a role in darunavir resistance although they are set 
in complex mutational backgrounds. Using a combination of statistical and 
machine learning techniques, we identify individual and paired residue positions 
within the protease that are key in perturbing the dynamic ensemble of the 
protein. These findings reveal that primary mutations are not solely responsible 
for driving resistance. Furthermore, the techniques used in this study are 
applicable to larger and more diverse drug resistant protein variants. Identifying 
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which variable positions have the largest impact on drug resistance may be 
useful in the future of structure based drug design.
3.2 Introduction
The HIV-1 protease inhibitor (PI) darunavir (DRV) is highly potent against 
its target. Unlike first generation PIs, DRV is able to withstand many mutations 
both within and outside of the proteins’ active site [135, 194]. Given its high 
barrier to resistance, single mutations do not pose a threat to DRV targeting. 
Underlying substitutions responsible for cross-resistance to other PIs are still 
fairly susceptible to DRV inhibition [195]. Contributing factors to DRV’s high 
genetic barrier to resistance include the tight binding affinity (Kd = 4.5 x10-12 M 
[182]), extensive hydrogen bonding with several active site backbone atoms 
[196], hydrophobic contacts within the active site and a good fit within the 
substrate envelope [183]. However, even with all these key attributes the 
protease is still able to develop complex interdependent mutational patterns to 
evade DRV inhibition. 
In such complex multiple mutational patterns, while active site mutations 
physically alter inhibitor binding and are readily identified, the role of mutations 
beyond the active site is not completely clear. The widely accepted notion is that 
accessory mutations had the sole purpose of balancing the destabilizing effects 
of primary active site mutations [86]. However, accessory mutations’ direct role in 
drug resistance has not been extensively probed [69, 148, 152, 197] and even 
less well known are which specific variable positions outside the active site play a 
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role in resistance [188]. Specifically, some mutations within the active site that 
arise to darunavir are readily explained by the substrate envelope hypothesis. 
For instance, DRV resistance associated mutations I84V, I50V, V32I and I47V all 
lay in positions where the inhibitor atoms protrude beyond the substrate envelope 
at the active site [134]. However, in clinical trials DRV selected for several non 
active site (secondary or accessory) mutations at positions 11, 33, 54, 73, 76, 85, 
and 89 among others, [186, 198] and the role of these mutations in DRV 
resistance is not clear.
Previously, to gauge how secondary mutations away from the protease 
active site, both associated with DRV resistance and not associated with DRV 
resistance, could play a role in protease inhibitor susceptibility, we examined 
several single mutations and one double mutation variant of HIV-1 protease. 
These mutations included V32I at the periphery of the active site, and a 
combination of V32I/L33F. In addition we examined the distal DRV resistance 
associated mutation (RAM) L76V and the non-DRV RAM L90M. A careful 
investigation of the crystal structures and molecular dynamics simulations of 
these variants bound to DRV showed that while these distal mutations alone do 
not drive significant levels of resistance, they were all able to perturb the network 
of hydrogen bonds within the protein, thereby propagating the effect to the 
protease active site causing slight loss of affinity. This network model provided a 
general understanding as to how mutation of residues may communicate with 
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one another and why some co-mutant relationships may be synergistic or 
redundant.
In this study we further investigate the role of mutations both at and away 
from the active site in complex combinatorial backgrounds of a set of protease 
variants, and compare to the WT and single/double site mutants examined 
previously. Specifically, this study seeks to determine which variable positions in 
the protease are responsible for the distinguishing patterns of resistance within 
the heavily mutated variants. Several DRV-resistant protease variants were 
selected from viral passaging experiments as well as patient-derived variants 
from the HIV Drug Resistance Database at Stanford University 
(hivdb.stanford.edu). Extensive (triplicate) 100 ns MD simulations were 
conducted on the panel of 15 protease variants (SF-2 and NL4-3 WTs and 13 
variants) all bound to DRV. From the resultant MD trajectories, interactions within 
protease and with DRV were monitored by hydrogen bond occupancies, internal 
active site Cα-Cα distances and van der Waals energies. For each of the data 
sets a combination of statistical and machine-learning techniques was used to 
identify which residue positions contribute the most to the calculated properties 
and protease resistance. These analyses find that the hydrogen bonding patterns 
among the panel of protein variants distinguish single/double mutants from the 
more complex variants. Mutations in the hydrophobic core (A71V) and near the 
flap regions (R41K) also impact the hydrogen-bonding network. In addition to the 
hydrogen bonding, the primary mutation I84V in conjunction with the accessory 
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M46I and several other accessory mutations give rise to distinguishing patterns 
of interdependency in hydrophobic (vdW) contacts with DRV. Finally, we find via 
protein structure network analyses that, some highly mutated patient variants 
exhibit similar dynamic cross-correlations to both WT enzymes. This result 
implicates some accessory mutations as having a dual role, aiding in both 
resistance and the enzyme’s ability to recapitulate more WT like enzymatic 
behavior in the presence of drug.
3.3 Results 
To determine which variable positions specifically impact the structural 
and dynamic properties of protease-DRV binding, a combination of inhibitor 
bound crystal structures and homology models were used as input for molecular 
dynamics simulations. Using the resulting trajectories, hydrophobic contacts and 
internal Cα-Cα distances were calculated, and the hydrogen bond occupancies 
were monitored for the panel of protease variants. 
3.3.1 Convergent evolution drives protease resistance in independent viral 
lineages
A diverse panel of fifteen HIV-1 protease variants were chosen with a 
broad range of sequence substitutions containing single site mutants and more 
heavily mutated multi-drug resistant proteases (MDR-PRs). Both the SF-2 and 
NL4-3 wild-type proteases were used as controls for the variants in the panel. 
The wild-type proteins share 95% identity, varying at positions 7, 14, 41, 63 and 
64, and they both have high susceptibilities to DRV in single-digit picomolar 
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values (SF-2 with a KI of 2 pM [169], and NL4-3 with an EC50 of 4 nM), (Table 
3.1). 
Table 3.1 Ki, IC50 and EC50 values as determined by the Schiffer laboratory, 
Monogram Biosciences and the Swanstrom laboratory, respectively. Note that 
IC50 value for NL4-3 WT protease is the median value for inhibition with DRV.
Ki Monogram
(IC50)
Swanstrom
EC50
Raw Fold Change Raw Fold Change Raw Fold Change
SF-2 2pM -
NL4-3 ~0.8nM 3.98nM -
L76V 3pM 1.5 - - - -
L33F - - - - - -
V32I 7pM 3.5 - - - -
V32I/
L33F(DM)
45pM 22 - - - -
I84V - - - - - -
I93L - - - - - -
Swan8 - - - - - -
Swan10 - - - - - -
ATA21 - - >200 - -
KY26 - - 89.6nM 112 1.16M 291
SLK19 - - 19.2nM 24 32.5nM 8
VEG23 - - >200 7.8M 1959
VSL23 - - 31.2nM 39 320nM 80
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Of the MDR proteases in the panel, two were obtained from long-term viral 
passaging experiments, conducted under DRV selective pressure by the 
Swantsrom laboratory at UNC-Chapel Hill. The remaining MDR proteases were 
obtained from the HIV Drug Resistance Database at Stanford 
(hivdb.stanford.edu). The patient-derived MDR-PRs contain between 19 and 26 
substitutions when compared to the SF-2 WT protease. Taken together, the 
panel of 15 proteases has sequence variations at a total of 50 of the 99 amino 
acid positions within each monomer (Figure 3.1). 
Figure 3.1 Proteases derived from multiple ancestors converge evolutionarily 
to drive resistance to DRV. Sequence alignment of all proteases included in the 
panel. Mutations are highlighted compared to the SF-2 WT protease (PDB code 
1T3R. PDB code 2HB4 denotes NL4-3 WT). 
Although we cannot infer viral population ancestry and temporal treatment 
history for each of the patient derived proteases, they share common 
evolutionary changes with one another and also with those MDR-PRs derived 
from viral passaging experiments. Based on the years that the samples were 
isolated and the high resistance to DRV inhibition, there is a possibility that one 
88
patient, VEG23, may have been treated with DRV. Interestingly, the patient-
derived ATA21 variant is highly similar to the patient-derived VEG23 and serially 
passaged Swan 8 variants, sharing sequence identities of 88% and 80% 
respectively (Figure 3.2). 
These shared sequence identities within the panel emphasize the role of 
underlying cross-resistance to DRV among the patient isolates. Although we do 
not know whether variant ATA21 was exposed to DRV, we do know that variant 
Swan8 was exposed exclusively to DRV. The level of resistance to DRV that 
these variants exhibit, along with their high percentage identity suggest that 
under the selective pressure of inhibition the phenotypes of these proteases have 
converged perhaps driving similar mechanisms of resistance. The relations 
between all sequences can be seen in the phylogenetic tree in Figure 3.3. 
SF#2% NL4#3% L76V% L33F% V32I% V32I_L33F% I84V% I93L% Swan8% Swan10% ATA% KY% SLK% VEG% VSL%
SF#2% 100# 95# 99# 99# 99# 98# 94# 94# 87# 85# 79# 74# 81# 77# 77#
NL4#3% 95# 100# 94# 94# 94# 93# 99# 99# 92# 90# 78# 75# 80# 76# 78#
L76V% 99# 94# 100# 98# 98# 97# 93# 93# 86# 86# 78# 73# 80# 76# 76#
L33F% 99# 94# 98# 100# 98# 99# 93# 93# 88# 86# 80# 75# 80# 78# 78#
V32I% 99# 94# 98# 98# 100# 99# 93# 93# 88# 86# 80# 75# 80# 78# 76#
V32I_L33F% 98# 93# 97# 99# 99# 100# 92# 92# 89# 87# 81# 76# 79# 79# 77#
I84V% 94# 99# 93# 93# 93# 92# 100# 98# 93# 91# 79# 74# 79# 77# 77#
I93L% 94# 99# 93# 93# 93# 92# 98# 100# 91# 89# 77# 74# 79# 75# 79#
Swan8% 87# 92# 86# 88# 88# 89# 93# 91# 100# 98# 80# 76# 75# 78# 75#
Swan10% 85# 90# 86# 86# 86# 87# 91# 89# 98# 100# 78# 75# 75# 78# 75#
ATA% 79# 78# 78# 80# 80# 81# 79# 77# 80# 78# 100# 79# 73# 88# 74#
KY% 74# 75# 73# 75# 75# 76# 74# 74# 76# 75# 79# 100# 68# 77# 74#
SLK% 81# 80# 80# 80# 80# 79# 79# 79# 75# 75# 73# 68# 100# 73# 80#
VEG% 77# 76# 76# 78# 78# 79# 77# 75# 78# 78# 88# 77# 73# 100# 75#
VSL% 77# 78# 76# 78# 76# 77# 77# 79# 75# 75# 74# 74# 80# 75# 100#
Figure 3.2  Sequence identity matrix for all 15 proteases in the panel. High % 
identity values are colored blue, low % identities are colored red.
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Figure 3.3  Neighbor-joining phylogenetic tree of all 15 protease variants. 
Color annotations are similar between variants with high sequence similarity.
3.3.2 Sequences of multi-drug resistant mutants are predictive of protease 
dynamics
The SF-2 WT (PDB: 1T3R), L76V, V32I and V32I/L33F were the variants 
with available crystal structures. The NL4-3 WT and remaining variants were 
modeled based on the DRV bound wild-type 1T3R structure. The crystallographic 
water molecules, including the important bridge water between the inhibitor and 
the protease flaps, were preserved in each model. Three replicates of fully 
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hydrated 100 ns MD simulations of each DRV complex were performed and 
analyzed. 
The root mean square deviations (RMSD) reveal that the accumulation of 
mutations from single site to patient-derived variants progressively alters the 
dynamics of the proteins. When compared to the SF-2 WT, the L76V, ATA21, 
KY26 and VEG23 variants deviate the most from their respective starting 
structures, whereas each of the variants derived from viral passaging 
experiments only deviate slightly over the duration of the simulation when 
compared to the NL4-3 WT (Figure 3.4). 
The changes in Cα root mean square fluctuations (RMSF) about the mean 
increase from single to patient-derived variants with the most pronounced 
changes in fluctuation seen in the flaps, flap elbow, and lower loop regions of the 
L76V, I84V, ATA21 and VEG23 proteins while the catalytic aspartate residues 
remain rigid across the simulations (Figure 3.5). Interestingly, hierarchical 
clustering of per-residue RMSF for the fifteen variants results in groupings of the 
variants in a similar fashion as within the phylogenetic tree in Figure 3.3. This 
overlapping of clustering suggests that sequence similarity alone may be a 
predictor of similar backbone dynamics (Figure 3.6).
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Figure 3.4  Protease dynamics is impacted by high number of mutations. Top 
left: Single mutants L76V, V32I, L33F, and V32I+L33F as well as patient-
derived variants are compared to the SF-2 WT(Bottom).  Top right: Variants 
I84V, I93L, Swan8 and Swan10 are compared to the NL4-3 WT. For graphing 
purposes half of the total amount of frames incurred over the 100ns 
simulations are shown. “Frame” on the x-axis is interchangeable with “Time” 
as 10,000 frames is the equivalent of 50ns.
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Figure 3.5 Overlay of Cα RMSF with same groupings as in Figure 3.4, where 
arrows pointing to protease highlight areas of significant change.
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Figure 3.6 Dendrogram of per-residue RMSF for the 15 variants in the panel. 
All heavy atoms are included in the calculation of per-residue RMSF but 
hydrogen atoms are excluded.
3.3.3 Hydrogen bonds elicit changes in dynamics brought about by 
combinations of mutations 
To characterize alterations in the hydrogen bonding observed among the 
different variants and to determine which variable positions best explain these 
alterations in hydrogen bond network among the proteases in the panel, a total of 
143 hydrogen bonds were monitored over the course of the simulation. Included 
in these measurements were 111 main chain hydrogen bonds including those 
from protein to DRV and the 32 side chain hydrogen bonds formed both with 
DRV and with other residues.  With an expanded panel of protease variants, 
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relative to our earlier studies, and such a long list of hydrogen bonds, the use of 
algorithms for detecting patterns of altered occupancies and identifying specific 
mutations that may underlie these alterations becomes essential. Accordingly, 
we employed a combination of principal component analysis (PCA), for helping to 
detect alterations, followed by hypothesis testing based upon amino acid 
substitution at specific sites in the protease. To begin, a 15x15 correlation matrix 
of mean occupancies for these 143 hydrogen bonds was computed and used for 
PCA (see methods for details). We note that 1) the first principal component 
accounts for nearly all (>85%, Figure 3.7) of the inter-variant variance in 
hydrogen bond occupancies and 2) the distribution of variants along this 
component is bimodal.  
Using the 111 main chain hydrogen bonds, in the plot of the first two 
principal components, we note that the resistant variants tend to have higher 
values of the first principal component (denoted as u1) than the more susceptible 
variants, including the two WT strains. In order to infer that substitutions at 
specific positions account for the distribution of variants (density, ρ(u1)) along u1 
we conducted hypothesis tests (Wilcoxon rank sum) for pairs of distributions 
defined by the presence or absence of a mutation. The null hypothesis is no 
difference between the means of these two distributions. There is a lower bound 
on the p-value, defined by ρ(u1). The protease panel was partitioned into two 
groups such that their difference along the first principal component was maximal 
(low PC1 and high PC1) (Figure 3.6). Table 3.2 summarizes the results of these 
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tests, identifying A71V as the single mutation that best accounts for the spread in 
hydrogen bonding patterns among the variants in our panel. Segregating the 
variants based on this mutation, we find that Swan 10, KY26, SLK19, VEG23 and 
VSL23 all contain changes at position 71.
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Figure 3.6  Fifteen sequence variants projected on to the first two principal 
components for the correlation matric of 111 mean main chain hydrogen 
bond occupancies. Variants colored in blue have high PC1 values and variants 
colored in violet have low PC1 values.
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Figure 3.7  The variance of hydrogen bond occupancies is accounted for by the 
first principal component (eigenvalue spectrum). 
Table 3.2  List of top five positions that underlie changes seen in hydrogen 
bonding patterns.
Residue 
Position
P. Value
           71 0.000666
10 0.00133
54 0.00133
37 0.00439
35 0.00586
2 4 6 8 10 12 14
0.0
0.2
0.4
0.6
0.8
i
i/TrC
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To investigate further, combination of substitutions that better recapitulate 
the segregation of variants into low and high PC1 were identified. We found no 
pair or other combination of substitutions that can better account for the observed 
distribution of variants along u1 than does the A71V mutation alone (Table 3.3 
and Figure 3.8). 
Table 3.3  List of top five position pairs found to most likely underlie changes 
seen in hydrogen bonding patterns. 
Residue 
Position 
1
Residue 
Position 
2
P. Value
41 71 0.000666
10 41 0.00133
10 54 0.00133
41 54 0.00133
10 71 0.00146
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Figure 3.8 Fifteen sequence variants projected as in Figure 3.6. Variants 
colored blue contain substitutions at residues 71 and 41 with variants KY26, 
SLK19, VEG23, and VSL23 also containing substitutions at positions 10 and 54.  
Moreover, the variance within this panel can be better explained by 
classifying the variants into those containing mutations at 10, 54, 71 and 41 
simultaneously, and those that do not. Only the patient variants mentioned above 
contain this combination of mutations. While the importance of residue 41 initially 
seems miniscule, it is one of five residue changes that distinguish those variants 
in our panel in an NL4-3 background from those in the SF-2 background. This 
finding suggests that perhaps mutations at positions 71, 54, and 10 have a 
greater effect on the hydrogen-bonding network of those variants in the NL4-3 
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background relative to those variants with an SF-2 background in this panel. 
Also, because mutations 10, 54, 71 and 41 are very distal to the active site, these 
additional mutations may perhaps be relaying information about the global 
dynamics of the protein consistent with our original hypothesis that mutations 
perturb the dynamic ensemble of the protease via the network of hydrogen 
bonds. The findings here correlate well with the raw hydrogen bond occupancy 
data, as the majority of variants in the panel contain very pronounced changes 
about the high 60s/lower 70s beta strand-loop-beta strand region (Figure 3.9). 
Figure 3.9  Departure from the mean calculated from variants as segregated in 
Figure 3.6.  
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3.4 The role of non-active site mutations elucidated via van der 
Waals contacts 
Using the aforementioned methods, amino acid substitutions that played 
key roles in altering the hydrophobic contacts of the protease with DRV were 
determined. The mean van der Waals (vdW) contact energies between the 
protease active site residues and DRV were calculated over the trajectory for 
each of the variants in the panel. Energies were collected for 64 amino acids 
within the protease active site during simulation. Inspecting the distribution of the 
variants along the first principal component we find the variants segregate 
differently than the internal hydrogen bonding. Interestingly, the variants KY26 
and SLK19 segregate with both the WT proteases and some single mutants close 
to this group as well, while the I84V and L76V segregate with the more complex 
variants (Figure 3.11). 
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Figure 3.10 Eigenvalues (proportion of variance) for the fifteen protease 
variants.
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Figure 3.11  Protease variants projected onto top two principal components 
and partitioned such that their differences along the first principal component 
are maximal. Variants colored in violet have low PC1 values and those colored 
blue have high PC1 values.
Following the positional scanning and hypothesis testing approach that we 
used to examine the hydrogen bond occupancies we determine that I84V is the 
most predictive single site substitution for classifying the variants (Table 3.4). 
Segregating the variants based solely on the presence of I84V captures most of 
the base partitioning, such that variants ATA21, VEG23, KY26, Swan8, Swan10 
and, necessarily the I84V single mutant, are distinguished from the remainder of 
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the protease panel (Figure 3.13). Among the candidate pairs of mutational sites, 
the pair of residues that is most predictive of the perturbations of the vdW contact 
energies is I84V and M46I (Table 3.5). Segregating the variants based on this 
combination of mutants, ATA21, VEG23, Swan8 and Swan10 can be distinguished 
from the rest of the panel (Figure 3.14).  
Table 3.4  List of top five residue positions that most likely to explain variance 
in the vdW data.
Residue 
Position
P. Value
84 0.00466
46 0.00759
13 0.0175
57 0.0307
35 0.0395
Table 3.5  List of top five residue position pairs found to most likely explain 
the variance in the vdW data.
Residue 
Position 1
Residue 
Position 2
P. Value
13 84 0.00146
32 84 0.00146
33 84 0.00146
46 84 0.00146
14 84 0.00466
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Figure 3.12 Protease variants projected as in Figure 3.12 and partitioned 
based on the presence (blue) or absence (violet) of I84V.
Furthermore, combinations of substitutions at positions 13, 32, and 33 
combined with I84V were predictive of the distinguishing patterns within the vdW 
data. All four of the variants containing a change at positions 84 and 46 also 
contain mutations I13V, V32I and L33F. This finding suggests that once 
mutations are developed at I84 and M46 the subsequent changes may become 
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Figure 3.13 Protease variants as in 3.12 and partitioned based on the presence 
(blue) or absence (violet) of I84V and M46I.
obligatory in the obstruction of protease-DRV binding. Among the 64 residues 
that make hydrophobic contacts with the protease, residues within or adjacent to 
the active site, specifically D30, I50 and I84 in chain A and R8, D29, D30, G27, 
G48, V82 and I84 in chain B, are perturbed the most due to the presence of 
accessory mutations, as indicated by the departure from the mean for all 
residues across the 15 proteases (Figure 3.14, see methods).  
That the distinguishing variations in hydrophobic contacts mostly impact 
generally immutable active site residues suggests that the role of preserving 
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hydrophobic contacts upon inhibitor binding is crucial for sustained targeting 
(Figure 3.14). Mapping the difference in departure from the mean values onto the 
structure further details how active site residues are impacted by mutations 
(Figure 3.15). The findings from the vdW data set are in good agreement with 
DRV binding in general, in that DRV employs hydrogen bonding and hydrophobic 
contacts to maximize inhibition. Figure 3.16 inset displays the exemplary 
relationship between I84’ and its proximity to the P1’ phenylalanine mimicking 
moiety in DRV. The change from isoleucine to valine would reduce the close 
packing of the isoleucine side chain and the inhibitor. 
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Figure 3.14 Departure from the mean across all 15 variants for enzyme-
inhibitor van der Waals energies. Colors are preserved from initial 
partitioning in Figure 3.14.
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Figure 3.15 Difference in departure from the mean mapped onto protease 
structure, colored from highest variability (red) to no variability (gray). Inset; 
view of I84’ (red mesh) versus V84’ (gray mesh) packing with DRV.
3.5 Dynamic cross correlations may link changes in van der 
Waals contacts to clinical measures of resistance
In the vdW analyses above, the variants KY26 and SLK19 closely group 
with the single and double site mutants along PC1, which is in contrast to the 
other patient-derived variants. To examine whether the global dynamic network 
of these variants are also more similar to wild type protease, the community 
structures were evaluated along with the underlying dynamical cross correlation 
109
networks and edge betweenness for all 15 variants in the panel. The trajectory 
frames from the MD simulations of the variants were used to conduct the 
dynamic protein structure network analysis using the Bio3D package for R [199]. 
Comparison of the SF-2 and NL4-3 wild-type proteases cross correlation 
matrices, community structures, and betweenness centrality values reveal that 
the differences at five amino acid positions between the two, reflect in their 
dynamic networks have a slightly different make up (Figure 3.16).
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Figure 3.16  Comparison of protein structure networks of SF-2 and NL4-3 WT 
proteases. A. Community structure networks shown in 3D mapped onto the 
protease (left) and simplified in 2D (right).  B. Histograms of betweenness 
centrality values, with values mapped onto the protease structure shown in 
the inset of the graph. C. Dynamic cross-correlation network values mapped 
onto the protease structure. Positive correlations are blue and negative 
correlations are red. D. Dynamic cross correlation matrices, with the same 
coloring as in C. Annotations on the left side bar and bottom side bar are 
representative of community structures seen in A.
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3.5.1 Community Structures
One way to interpret data contained in a cross correlation matrix is to look 
at community structures. Overall, the residue communities that lie within each 
protease align with the lineages of origin (Figure 3.17). The exception to this 
trend comes along with the more highly mutated passaged and patient derived 
variants. While the ancestral or temporal treatment information of the patient-
derived variants are unknown, Swan 8 and Swan 10 are from an NL4-3 
background and resolve to have a community structure similar to those variants 
from the SF-2 lineage. ATA21, KY26, and VEG23, which align closely in sequence, 
contain community structure networks similar to variants of the SF-2 lineage. 
Contrarily, variant SLK19 has a similar community structure network to the NL4-3 
wild-type along with I93L. A notable secession from this seemingly ancestral drift 
are the community structures of I84V and VSL23, which take on very distinct 
community structures but are more aligned with the NL4-3 structured variants 
(Figure 3.18). The community analysis provides insight into the protease’s 
resiliency by displaying how, in the presence of combinations of mutations, the 
protease is able to alter its phenotypic composition to sustain resistance. 
Interestingly, the highly mutated patient variants KY26 and SLK19, which 
partitioned with the wild-type proteases in the vdW analysis, display community 
structures that are overall more similar to wild type than the other patient-derived 
variants.
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Figure 3.17  Example community structure networks mapped on to the 
protease. A-H; Community structure networks for proteases V32I_L33F (DM), 
I93L, Swan 10, SLK19, Swan 8, KY26, VSL23 and I84V respectively. Both A and 
C have highly similar community networks to the SF-2 protease while B and D 
have networks similar to the NL4-3 protease. E and F have similar community 
networks as the SF-2 protease but there are some residues that have switched 
from the orange communities seen in A and C in to the gray community. G and 
H have the most highly dissimilar community structures compared to the two 
WT proteases.
3.5.2 Girvan-Newman Edge Betweenness
In the community structures mentioned above, each residue is taken as a 
node or a vertex. Within and between communities these nodes or groups of 
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nodes respectively are connected through edges. Examining the connectivity of 
these edges within and between communities gives rise to betweenness 
centrality. Betweenness centrality is an indicator of a node’s centrality (or 
importance) in a network [200]. Those nodes with higher betweeness centrality 
can be deemed as hubs essential for communication from one community to 
another. The inspection of betweenness centrality by residue plots or 
“betweenness spectra” shows that there is nearly an even split between those 
variants that make use of residue 83 as a hub and those that do not. This use of 
residue 83 is interesting because N83 is conserved and lies in the middle of the 
80s loop, between two highly variable residues, V82 and I84. Hence, residue 83 
may be important for communication to this region of the active site. There are 
many commonalities across the 15 proteases with respect to betweenness 
centrality, especially the use of residues 5, 8, 10 and 22 in one chain as hubs. 
The use of these residues is modified slightly in variants KY26 and SLK19   which 
make use of residues 5, 9, and 23 as hubs (Figure 3.19). The significance of this 
observation will be discussed below.
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Figure 3.18  Betweenness spectra. A-F; Histrograms of betweenness centrality 
values for variants V32I, V32I_L33F(DM), ATA21, VEG23, SLK19, and KY26 
respectively. The majority of variants in the panel use residues 5, 8, 10 and 22 
for communication between the termini and the active site region of the 
protease while SLK19 and KY26 do not. Inset for all figures in the panel are 
the betweenness centrality values mapped on to the protease structure. 
3.5.3  Dynamic Cross Correlation Matrices
The dynamic cross correlation matrices are the basis of the network 
analyses presented above and direct examination of them can yield additional 
insight. Within these matrices, residues that move in the same direction have 
positive cross correlations and those that move in opposite directions have 
negative cross correlations. When the movement of two residues is not 
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correlated, the cross correlation value is zero. Domains of contiguous residues, 
such as in an alpha helix or beta strand, would give rise to significant positive 
correlations emanating from the diagonal of the matrix [201, 202]. Visual 
inspection of the matrices and corresponding mapping of cross correlation 
coefficients onto protease crystal structures shows drastic changes between 
certain variants (Figure 3.19). For example, variant L33F loses both positive and 
negative inter- and intra-monomeric cross correlation peaks while variant VSL23 
gains both positive and negative cross correlations relative to wild-type protease. 
There is also some overlap between Cα-Cα distances of certain residues and the 
corresponding increase or decrease in signal seen in the cross correlation 
matrices (Figure 3.19). The trend of either losing key positive cross correlation 
peaks or gaining negative cross correlation peaks can be seen throughout the 
variants except in patient variants KY26 and SLK19. Both KY26 and SLK19 are able 
to retain key positive inter-monomeric cross correlation peaks and seemingly 
exchange negative inter-monomeric cross correlation peaks in the active site. 
This suggests that KY26 and SLK19 contain combinations of mutations that are 
capable of rendering the enzyme resistant to the inhibitor but able to retain wild-
type-like conformational dynamics and function in the presence of drug (Figure 
3.20).  
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Figure 3.19 Atomic distances between residues 80 and 80’ and dynamic cross 
correlation matrices. B-F; Dynamic cross correlation matrices for variants 
L76V, L33F, VSL23, SLK19, and KY26 respectively. Regions containing peaks 
for correlations between residues 80 and 80’ are underlined in red. In these 
regions peaks for residues 80 and 80’ get smaller as the interatomic distances 
move further apart and larger as they get closer together as seen in A.
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3.6 Discussion
In this study, the effects of mutations on protease structure and dynamics 
have been investigated via hydrogen bonding, hydrophobic contacts with the 
inhibitor, and the overall networking within the protein. Specific residues have 
been identified that account for the variance in these properties, comparing multi-
drug resistant variants to that of the lesser or non-mutated counterparts. While 
the active site mutations impede inhibitor binding in an intuitive manner, the 
constellation of mutations that arise throughout the rest of the protein, as is the 
case with DRV, have long been thought to aid in recovery of viral fitness only. To 
better understand the role of non-active site mutations in drug resistance, 15 
protease variants have been chosen, which taken together contain substitutions 
at 50 of the 99 amino acid positions within the enzyme.
The accumulation of mutations within a drug target allows the balance of 
substrate processing versus inhibitor binding to tip in favor of the former. The 
HIV-1 protease is a very small protein but exemplifies a high level of resiliency 
under selective pressure. While the robustness of a mutated enzyme may seem 
less comparable with its more replication competent non-mutant counterparts, 
drug resistant protease variants are able to adapt and perpetuate viral escape 
and growth just as well given their new amino acid composition and environment. 
We have shown previously that mutations compromise the hydrogen 
bonding and van der Waals contacts necessary for DRV binding to ensure that 
the mutations render the protein resistant while retaining its biological function 
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[169]. In this study, we used a novel combination of molecular dynamics 
simulations and unsupervised machine learning to identify and characterize 
those positions that are key to DRV binding. The resulting positions are highly 
conceivable given their prior examinations by other laboratories. For instance, 
position 71 was found to be a major contributor to the variance of the hydrogen 
bonds. The A71V mutation has been shown previously to be a key mutation in 
the re-stabilization of the enzyme in the presence of major mutations such as 
I50L/V, and has also been shown to propagate its effects from its resident 
position in the cantilever region of the protease to the active site via the hydrogen 
bond network of the protein [139, 141, 149, 203-205]. Because the mutations that 
were found to be highly predictive of changes in the dynamic hydrogen bonding 
within the protein are all distal to the active site, this suggests that the impact of 
mutations on the hydrogen bonding network is spread throughout the protein 
probably affecting the overall dynamic ensemble of the protein, consistent with 
our previous findings [169].
Mutation I84V is a mainstay in protease inhibitor cross-resistance. The 
change from the bulkier beta-branched isoleucine to the smaller valine has been 
the Achilles heel of PI treatment since its first emergence against saquinavir 
(SQV) treatment [206]. M46I was thought to only be a compensatory mutation 
[130] until early MD studies found it to be a key modulator of flap dynamics [207].  
The pair of I84V and M46I has been long studied as a major/minor co-mutant 
pair in the midst of other compensatory mutations able to drive resistance to 
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early PIs [130, 208]. The other mutations that were atop the list of likely variants 
underlying the variance seen in the van der Waals contacts all lie outside of the 
active site (with the exception of the peripheral V32I) and have been explored 
thoroughly for their compensatory effects [188]. Figure 3.16 illustrates that the 
residues with the highest variability in vdW contact energies lie within the active 
site (G48, I50, I84, G27’ and I84’); however the other mutations with high 
variability are either juxtaposed or distal to the active site. The calculation of the 
departure from the mean (σ*) explicitly demonstrates that mutations outside of 
the active site are in fact able to perpetuate changes that occur at generally non-
mutating positions within the active site necessary to perturb vdW packing crucial 
to DRV binding. 
The dynamic cross correlation matrices and variations of these matrices 
(i.e. network community analyses and betweenness centrality) show that the 
presence of combinations of mutations influence residue communication 
pathways within the protease. Visual inspection of the cross correlation matrices 
clearly display the degradation of residue communication caused by mutations 
such as the single mutations L33F and L76V, or more complex variants such as 
VSL23 . Close observation of all the cross correlation matrices reveals that the 
majority of the mutants in the panel have not achieved the appropriate 
combinations of mutations to render them having wild-type-like dynamics (likely 
biologically functional) and inhibitor resistant at the same time. For most of the 
variants, there is either an accumulation of increasing negative cross correlations 
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or a reduction of positive cross correlations or loss of both simultaneously. 
However, in the case of variants KY26 and SLK19 the majority of positive intra and 
inter-monomeric cross correlations are retained while negative cross correlations 
involving active site residues are converted into positive correlations unique only 
to these two enzymes, relaying information about possible mechanisms they 
employ to confer resistance. 
Some indication of why variants KY26 and SLK19 group closely with the 
lesser mutated variants and the wild-type proteasess may lie in protein network 
analyses. Although these variants do not have similar community structures and 
the correlations between their respective betweenness centrality profiles are low, 
they do share unique patterning of both positive cross correlations (Figure 3.21) 
and edge betweenness at least in one monomer. 
Figure 3.20 Dynamic cross correlation peaks mapped on to structure of 
clinically derived variants KY26 and SLK19. Cylinder size is proportional to the 
cross correlation value. Blue cylinders denote most positively correlated 
(values 0.75-1) and red cyliners denote the most anti-correlated residues 
(values -0.5 - -0.4).
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This is evident in that KY26 and SLK19 make use of residues 5, 9 and 23 as hubs 
for communication in one monomer while all of the other proteases within the 
panel use a 5-X-10-22 pattern where X can be residue 7, 8, or 9. Perhaps the 
makeup of these variants has allowed them to use an alternative route for 
communication from the termini to the active site that does not involve residues 
that are prone to mutation and thus allows for inhibition evasion. In keeping with 
this hypothesis, both residues 10 and 22 are mutated in other variants within the 
panel; residue 10 also forms hydrogen bonds with residue 8, which could mean 
that a change at position 10 could be detrimentally propagated through to the 
active site. The use of residues 5, 9, and 23 appears to be more stable in that 
residue 9 hydrogen bonds to residue 24 and residue 23 hydrogen bonds both to 
the non-mutating residue 83 and residue 85 so that communication along this 
pathway is less likely to be disrupted. Interestingly, the variant KY26 has the 
highest replication capacity among all the patient-derived variants, as assayed by 
Monogram Biosciences, and a medium-level resistance to DRV. In contrast, 
variant SLK19 has the lowest replication capacity and the lowest level of 
resistance to DRV but its activity is enhanced in the presence of RNA [209]. Both 
of these variants contain WT NC-p1 and p1-p6 substrate sequences, which 
suggests that KY26 has further accumulated the necessary mutations to cleave 
WT substrates and either SLK19 has not yet achieved the necessary mutations 
either in the protease or in the substrate to render it fit in the absence of drug. 
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Taken together it appears that these two variants have different combinations of 
mutations that have allowed them to tip the balance of substrate turnover and 
inhibition in favor of the former by using similar mechanisms to drive resistance 
to DRV.
The analyses presented here show how mutations outside of the active 
site impact DRV targeting. Consistent with the findings of Appadurai et al. [153], 
we find here that mutations distal to the active site, in single positions or highly 
complex combinations, are able to perturb inhibitor binding through changes in 
certain key interactions between the enzyme and inhibitor. We also find that 
changes in overall protein dynamics may be indicative of resistance. Because the 
proportion of variance within each of the data sets examined can be largely 
accounted for by the first principal component, linear regression models can be 
used to probe further which non-active site mutations play a role in resistance. 
The individual methodologies used for the analyses are not novel individually; 
however, combining a diverse set of protease variants and using a combination 
of MD simulations, machine learning and statistics to characterize key 
interactions and infer how mutations in complex combinatorial backgrounds work 
together to drive resistance is unprecedented. These techniques could be used 
together to probe other panels of proteases and PIs or proteases and substrates 
as well as other protein systems where the interdependency of resistance is not 
well understood to tease out the impact of mutations both at and distal from the 
active site in complex mutational combinations. 
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3.7 Methods
3.7.1 Protease Panel & Nomenclature
The panel of 15 proteases used in this study consisted of the SF-2 and 
NL4-3 WT along with 13 mutant variants. The WT proteases served as controls 
for the variants with respect to their subtype B backgrounds and laboratory origin. 
The L76V, V32I and V32I/L33F (PDB accession codes 3OY4, 4Q1X and 4Q1Y 
respectively) variants were taken from the previous study [169]. To this group of 
single mutants, a L33F single mutant was added. Another set of protease 
sequences were obtained from HIV-1 cell culture passaging studies in the 
presence of DRV. These sequencing and passaging studies were carried out by 
Dr. Sook-Kyung Lee and Dr. Shuntai Zhou of the Swanstrom laboratory at UNC-
Chapel Hill. Briefly, in vitro selections were carried out with DRV using an initial 
mixture of 26 variants, each containing a single resistance mutation. The 
selections were carried out with increasing inhibitor concentrations between 
1000-10,000 fold over IC50 measured in WT strains. Using the Primer ID-based 
paired-end MiSeq platform [210], mutations in the protease were analyzed at four 
time points at varying inhibitor concentrations. The variants in this set include 
models of single site I93L and I84V variants complexed with DRV along with a 
variant containing eight mutations (Swan 8) and a variant containing 10 
mutations (Swan 10) in an NL4-3 background. The final group of variants in the 
panel was selected from a set of patient-derived proteases in the HIV-1 drug 
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resistance database. This group of proteins contains 19–26 mutations compared 
to the SF-2 WT protease. 
Each patient variant is named based on which amino acid substitutions 
are unique to that variant and the number of mutations it contains compared to 
the SF-2 WT. For example, variant KY26 is the only variant that contains 
substitutions H69K and C67Y and it has 26 mutations. All other variants are 
named for the mutations they contain (e.g. variant I84V only contains this 
mutations). The V32I+L33F double mutant is referred to as DM for double 
mutant. 1T3R and 2HB4  PDB accession codes are used to refer to the SF-2 and 
NL4-3 WT proteases respectively. 
3.7.2 Homology Modeling & MD Simulations
The SF-2 WT, L76V, V32I and V32I/L33F had available crystal structures 
bound to DRV. The NL4-3 WT and remaining variants were all modeled based 
on the DRV bound 1T3R structure. The crystallographic waters, including the 
ever-important bridge water between the inhibitor and the protease flaps, were 
preserved in each model, as was the drug. Briefly, using the Prime Structure 
Prediction Wizard by Schrödinger (Release 2014-4, LLC, New York, NY [211, 
212]), each of the 11 variant sequences was used as a query to search for 
homologs via BLAST [213]. Both chains of PDB structure 1T3R were selected as 
templates to build the homodimer containing the appropriate variant sequence. 
Once the model was prepared, the structure was built retaining the ligand from 
the template structure. Waters from the template structure were merged into the 
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newly built variant structure and a series of refinement and minimization steps 
were undertaken to complete the model building using the Prime Protein Prep 
Wizard in Maestro. 
MD simulations were performed using the Desmond Molecular Dynamics 
System as previously described [138]. A set of three simulations totaling 300 ns 
was run for each of the thirteen variants and the two WT proteases for a total of 
45 simulations. To calculate hydrogen bond occupancies, the Simulation Event 
Analysis Tool within Maestro was used to determine the occupancies of 143 inter 
and intra-main chain and side chain hydrogen bond pair as well as those bonds 
made with the ligand. In order to facilitate analysis, including computation of the 
mean protein-ligand van der Waals interaction energies, Visual Molecular 
Dynamics (VMD) version 1.9.2 [192] was used to translate the Desmond 
trajectories to PDB format. 
3.7.3 Evaluation of Hydrogen Bonding and van der Waals Interactions
For each hydrogen bond pair, the donor heavy atom along with its 
hydrogen and the acceptor atom were specified for calculation of hydrogen 
bonding occupancy. For each frame, only pairs that satisfied the hydrogen bond 
geometric criteria as set forth by Schrödinger were chosen: the distance between 
hydrogen atom and acceptor atom must be at least 2.5 Å, the angle between 
donor heavy atom and its hydrogen and the acceptor must be at least 120°, and 
the angle between the hydrogen and acceptor heavy atom must be at least 90°.   
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The vdW contacts between the inhibitor and the protease were calculated using 
a simplified Lennard-Jones potential, following published protocols [191]. 
3.7.4 Principal Components Analysis and Statistical Testing
The hydrogen bond and van der Waals observations were combined into 
matrices of 15 x N, where N is the number of observations in each data set (fore 
example there were N=64 protein-ligand van der Waals energies per variant).  In 
order to remove the variance between different factors (e.g. between highly 
favorable van der Waals interactions and less favorable interactions) within a 
single protease variant and focus on the variance between variants, a 15 x 15 
correlation matrix, C, was computed. Principal components can be defined in 
terms of an eigenvalue problem: , which can be solved by the 𝑪𝑢𝑖 =  𝜆𝑖 𝑢𝑖
diagonalization of C: C = UC’U-1 where and the diagonal elements of C’ are 
ordered components of the variance (i.e. the eigenvalues λi). Because this 
transformation preserves the trace of matrix C (TrC = TrC’), and the proportion of 
total variance, TrC, that is explained by eigenvector ui is defined as . 
𝜆𝑖
𝑇𝑟𝑪
Eigenvalues and eigenvectors were calculated using an R interface to the 
LAPACK (Linear Algebra Package) library. With the van der Waals and hydrogen 
bonding data, the explained variance was dominated by the first eigenvector (or 
principal component) and hypothesis testing was use to interpret the spread 
among the different protease variants. For each amino acid position, the 
following quantity was computed in order to measure the standard deviation 
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within each class of van der Waals energies or hydrogen bond occupancies (i.e. 
high or low values of u1) of protease variants relative to the total mean:
  𝜎 ∗  =  ∑𝑁𝑐𝑙𝑎𝑠𝑠𝑗 = 1 (𝐸𝑗 ‒ 𝜇2)
where  and Nclass is the total number of variants classified  𝜇 =  ∑15𝑖 = 1𝐸 𝑖𝑣𝑎𝑛 𝑑𝑒𝑟 𝑊𝑎𝑎𝑙𝑠 
by sequence changes.  This deviation allows us to identify important, or at least 
highly variable residue interactions. All other figures and calculations were 
determined using various R packages [214-222]. 
3.7.5 Cross Correlation and Dynamical Network Analysis
From each concatenated 300 ns trajectory, 150 frames were used to 
conduct a dynamic cross correlation network analysis. VMD 1.9.2 was used to 
convert the fully hydrated all atom Desmond trajectories into DCD binary 
trajectory file format containing only the Cα atoms of the protein. Once each 
trajectory file was converted, network analysis was completed using previously 
published methods for the Bio3D package version 2.2 [199, 223] was used to 
compute the cross correlation coefficients, Cij, 
𝐶𝑖𝑗 = <  ∆𝑟𝑖 ∙  ∆𝑟𝑗 >( < ∆𝑟2𝑖 >  <  ∆𝑟2𝑗 > )
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for all Cα atoms pairs in R Studio version 3.1.3 [218], where Δri is the 
displacement from the mean position of the ith atom determined from all 
configurations in the trajectory segment being analyzed. Using this data, 
dynamical networks were constructed following the method of Luthey-Schulten 
and coworkers [202]. Briefly, this approach uses a weighted graph where each 
residue represents a node. Edges between nodes i and j are weighted (wij) by 
their respective correlation value (Cij ):
𝑤𝑖𝑗 =  ‒ log (|𝐶𝑖𝑗|)
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Chapter IV
Discussion
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4.1. Conspectus
Drug resistance occurs as the result of many different mechanisms; 
although there is a clear tie between the ascent of compensatory mutations and 
inhibitor treatment their roles in drug resistance are vastly overlooked. With the 
exception of some cancer and virus studies, compensatory mutations in drug 
resistant targets are largely studied in an evolutionary manner. While 
understanding the evolution of mutations within a target may be the first step in 
predicting further target evolution, solely studying the evolution of the target 
ignores key parameters that gave rise to both major and minor mutations initially. 
To understand the molecular mechanism by which resistance occurs, one 
must be able to break the resistance down into the mechanistic components and 
identify those inter-molecular interactions, be they bonded or non-bonded, that 
are vital for sustained inhibitor targeting. Elucidating the resistance mechanisms 
used by a target to compromise any or all of the necessary binding interactions is 
the first step of understanding the role of secondary mutations in resistance. 
Correspondingly, it is necessary to understand the relationships between 
secondary mutations alone and together with major or primary mutations. The 
phenomenon that secondary mutations restore fitness of the target in the 
presence and/or absence of drug is well documented however, to understand 
why certain combinations arise together to prompt further resistance goes back 
to the aforementioned point; one must decompose all parts of drug resistance in 
the system to elucidate mechanisms used by the target. 
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Identification and characterization of key interactions between inhibitor 
and target, in this thesis, DRV and HIV-1 protease, and subsequent methods 
used to determine mechanisms utilized by compensatory mutations to drive 
resistance should be broadly applicable to many systems. The specific methods 
may need to be customized for optimal understanding, but the general ideas of 
understanding the role of secondary mutations alone and in complex 
combinations and how they perturb key components of inhibitor binding is 
necessary to better prepare for resistance with the development of new 
inhibitors.
4.2. Implications for understanding the role of accessory 
mutations in drug resistance in other protein systems
4.2.1.  Application of techniques in this thesis to other drug resistant 
targets
The ability of mutations regarded as compensatory to restore the fitness 
lost due to drug resistant mutations is well documented in a number of cancers 
and pathogenic systems including viruses, bacteria, fungi and protozoa [177, 
224-226]. For example, compensatory mutations R222Q and V234M in influenza 
neuraminidase aid in loss of fitness driven by the oseltamivir resistant major 
mutation H274Y and increase surface expression of neuraminidase to cleave 
sialic acid moieities [227]. And while the elucidation of this combination of 
mutations was completed using a combination of experimental and phylogenetic 
tree analysis, the authors had previously used Bayesian inference to predict the 
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effect of the compensatory mutation R194G on increasing the stability of 
neuraminidase containing H274Y [228]. Similarly, single nucleotide substitutions 
mutations like c.9106C>G in the BRCA2 gene have been found to restore 
function of the BRCA2 protein, as this base change removes the ORF truncation 
at Q2960 by creating Q2960E mutation. Like many studies geared toward the 
elucidation of mechanisms of resistance, this study was able to identify certain 
mechanisms (mutations and deletions) using experimental methods and some 
bioinformatic analysis [229]. It is apparent from studies such as these that there 
is increasing need to employ computational techniques in combination with 
experiments in order to fully understand the mechanisms used by mutations 
distal to the active site of drug resistant targets. In chapter II, I decided to 
expound upon my static structural vdW and hydrogen bond findings by running 
molecular dynamics simulations to monitor these potential residue interactions 
over time. Without making use of this computational technique, many of the 
overall findings in this thesis may have not been uncovered. 
4.2.2. Residue “communication” should not be discounted in resistance
Understanding residue communication in mutable drug targets is essential 
for continued suppression of diseases. Residue communication is how a series 
of often neighboring residues impact each other in three-dimensional space, 
either through alterations in structure/packing or dynamics.  For instance, residue 
communication and the perturbations of residue communication has been probed 
in kinesin motor proteins extensively using MD simulations and correlation 
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network analyses[223, 230].  They were able to elucidate that various regions of 
the protein, including those that bind nucleotide and inhibitor, are highly coupled. 
They were also able to identify, through mutational analyses, amino acid sites 
that are crucial for the dynamic coupling between various regions in the protein, 
such E166’s role in coordination of the nucleotide and microtubule binding 
domains. Similarly, Young and coworkers [231] were able to determine that the 
connector region between the SH2 and SH3 domains of Src kinase becomes 
uncoupled in the presence of mutations that promote the lack of binding to a 
phosphorylated tyrosine, which would normally cause the SH2 domain to be 
coupled with the SH3 domain. The loss of binding and coupling of these two 
domains in the presence of mutations causes the Src kinase to be constitutively 
activated, which is detrimental to the regulation of the proteins’ active site.  Thus 
such residue communication has been studied in several large protein systems 
where inter-domain communication is crucial for function.
With respect to HIV-1 protease, the first report of domain communication 
was published in 1990[201]. In the decades since then the use of aforementioned 
methods to probe the changes in communication patterns in the presence of 
mutations and the impact that these changes have on inhibitor binding has been 
minimal. It hasn’t been until recently that a thorough investigation of the 
proteases communication patterns in a complex mutant background has been 
completed[153]. In this instance, Appadurai and coworkers were able to elucidate 
that communication from the proteases allosteric sites to the active site and the 
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flaps travels along a more direct path while in the mutant proteases, messages 
are relayed via multiple intermediate steps along a path. These indirect 
communication pathways in turn lead to uncoupled motions of the flaps, which 
disrupts inhibitor binding causing resistance. Whether the relationships between 
residues are manifested in more limited settings such as the relationship 
between residues V32, I47 and L33 in chapter II or in more complex settings as 
seen in chapter III, examining the global communication patterns and their 
impediment in the presence of mutations is imperative for avoiding drug 
resistance in key therapeutic targets. 
4.2.3. Incorporating information about accessory mutations into structure 
based drug design
Though the process of structure based drug design is highly rigorous and 
iterative by nature, the impact of potential drug resistance mutations against an 
inhibitor is often neglected. The DRV-resistant variants at the basis of chapter II 
were crystallized initially because they (with the exception of L90M) had been  
identified in the clinical POWER trials [186]. In these trials, clinically derived 
resistant isolates containing many cross-resistant mutations remained 
susceptible to DRV. However, during virological failure, DRV also selected for 
mutations outside the active site of the protease in both the POWER trials and 
clinical studies involving treatment naïve patients [198]. That this phenomenon 
was discovered in clinical trials and the possible mechanistic rationale that we 
were able to unearth in chapter II gives rise to the necessity of thoroughly 
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understanding and incorporating the roles of accessory mutations into drug 
design. 
Identifying a lead compound in the structure based design process is an 
arduous task. Ensuring that the compound is able to withstand the trade-off 
between toxicity, convenience, adaptability and potency in vitro and in vivo is 
difficult.  Because flexible inhibitors are less potent, the task of finding a rigid 
inhibitor that also has a high genetic barrier to resistance makes the entire 
process even more complex. However, time should be allotted for compounds 
identified as potential inhibitors of various drug targets to undergo more diverse 
analyses at certain points in the structure based drug design process upon the 
ascent of mutations. As is the case in chapter II we were not able to identify the 
influence of accessory mutations on the proteases active site until well after DRV 
was approved. If the analyses presented in both chapters II and III had been 
completed soon after the discovery of DRV RAMs in clinical trials and prior to its 
approval, perhaps DRV could have been improved upon to minimize the chance 
of virological failure. Because mutations are often inevitable, as is the case with 
HIV-1 drug targets, in the very least, integrating the types of analyses presented 
here would provide a comprehensive view of the causes behind potential 
drawbacks of otherwise highly potent compounds. 
136
4.3. The importance of understanding dynamics in drug binding
4.3.1. Relating protein dynamics to experimental inhibition data 
To understand the molecular basis for biological interactions such as 
protein-protein, protein-inhibitor, or protein folding interactions, the canonical 
procedure usually involves interpretation of some combination of structure, 
enzyme kinetics, and thermodynamic properties of the system under evaluation. 
These can involve many techniques including X-ray crystallography, NMR, 
various proteolysis and inhibition assays, circular dichroism, and isothermal 
titration calorimetry or differential scanning calorimetry to name a few. And while 
the data acquired from these techniques and others are invaluable to our 
understanding of many systems, newly discovered or thoroughly explored, they 
lack the ability to provide insight into protein flexibility and overall dynamics on an 
atomic scale. To explore atomic fluctuations in depth, molecular dynamics 
simulations are emerging as a way to study all molecular aspects of proteins 
mentioned above including binding kinetics and folding [232, 233]. 
In this thesis, I have combined both structural and dynamics data along 
with experimental data to try and capture as much information relating the 
structural and dynamic properties of the HIV-1 protease to experimental 
properties with regard to the roles of accessory mutations’ impact on drug 
binding. In a collaborative study with Dr. Marc Potempa at UNC-Chapel Hill, it 
can be seen that for the clinically-derived variants in chapter III, those variants 
with WT like dynamic properties and higher susceptibility to DRV also perform 
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substrate turnover better than the variants that are more resistant to DRV in the 
presence and absence of RNA [209]. We see through these studies that variant 
SLK19 has the highest fold change in initial velocity with the addition of RNA on 
processing the MA/CA substrate peptide. In chapter II, the levels of change in 
dynamics for the variants with one or two mutations directly aligned with the 
inhibitor binding constants measured. However, in the more complicated systems 
seen in chapter III, the connections between dynamics and experimental data are 
not so simple. This lack of correlation may partially be due the experimental 
difficulty in measuring the inhibition constant due to the high levels of resistance 
in the proteases. While I have been able to elucidate that KY26 and SLK19 are 
both dynamically similar to WT protease, aligning these findings with 
experimental and virological properties is not straightforward. Nevertheless, 
acquisition of various types of data provides a wealth of information about how 
much protein dynamics plays a role in the physical properties of protein binding 
and turnover. 
4.3.2. IV.II.B. Incorporating protein dynamics into inhibitor design
To fully understand the molecular determinants of inhibitor binding, it is 
necessary to first elucidate the molecular determinants of protein molecular 
recognition, be it to substrates, other proteins, or small molecules. Previous 
studies in our lab have determined that the HIV-1 proteases recognition is not 
based on sequence, as the enzyme is responsible for cleaving twelve sites 
lacking sequence homology. Alignment of substrate sites led to the discovery 
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that the substrates occupied a conserved volume and that the protease 
recognized the shape of the substrates rather than specific sequences. This led 
to the substrate envelope hypothesis [133, 189]. Further, our lab was able to 
determine that if inhibitors were designed to fit within the substrate envelope, 
they would more effectively inhibit the protease [134]. Our lab was also able to 
probe further the molecular determinants of protease-substrate binding by 
elucidating and validating the proteases recognition pattern with the dynamic 
substrate envelope [191, 234]. 
With respect to inhibitor binding, the canonical in silico analysis of ligand 
binding may not be enough to ensure that an inhibitor is able to outcompete 
naturally coevolving substrates. Our lab has found that use of dynamic substrate 
envelope in inhibitor design for both the HIV-1 and HCV NS3/4A proteases 
provides a strong scaffold for ensuring the robustness of inhibitors as the 
dynamic substrate envelope is preserved even in the presence of mutations in 
the enzyme and its naturally coevolved substrates [235]. Certainly incorporation 
of the dynamic substrate envelope along with the dynamics based analyses 
presented in this thesis together would promote lasting susceptibility of a drug 
target to an inhibitor.  
4.4. The value of machine learning for predicting probabilistic 
phenotypic drug resistance mechanisms
As mentioned previously, (statistical) machine learning is used heavily for 
prediction of mutational stabilities of proteins in evolutionary studies [228]. 
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Machine learning techniques are widely employed in the clinic to guide 
physicians and physician-scientists in choice of viable treatment options for 
virological success in naïve patients or in the event of necessitated treatment 
change as a result of virological failure in various viral systems [82, 236, 237]. In 
the case of HIV, treatment failure is often associated with drug resistance and 
thus genotypic resistance testing (GRT) is used to predict virological success of 
subsequent treatment. For prediction of virological response, experts’ rules 
(genotypic interpretation systems (GIS)) and (statistical) machine learning or a 
combination of the two are employed in several ways that typically fall under the 
GRT umbrella. The largest use of machine learning is incorporated into various 
treatment optimization systems (TOSs), such as EuResist, which is an integrated 
database that allows a user to input patient specific variables to determine the 
probability of virological success [238].  
Machine learning has also proven quite useful for in vitro phenotypic 
susceptibility studies involving decision trees and neural networks [239]. 
Although various factors, including drug-drug interactions, virus-host interactions, 
and viral mutational patterns make the prediction of virological response in vivo 
highly complex, machine learning has been suitably employed for prediction in 
vivo response with the help of sequence and clinical databases. While there are 
some machine learning based methods that do not utilize genotypic data for 
resistance testing, the goal of predicting virological outcome remains the bottom 
line for how computation is employed[237]. In summary, machine learning is 
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largely used to predict, one drug at a time, phenotypic resistance or susceptibility 
from viral genotypic data.
In this thesis, I am not using machine learning to predict virological 
response, instead I am using these powerful methods to examine the enzyme 
mechanistic response itself. The use of machine learning to predict virologic 
success or failures generally result in a shuffling of medications in hopes of 
maintaining sustained virological response. However, in depth probing of the 
mechanisms underlying the observed resistance responses is studied mostly in 
the laboratory and largely not with machine learning techniques. This thesis 
examines clinically derived phenotypic responses to DRV, dissects perturbations 
of key interactions driving DRV resistance, and determines which and how 
mutations impact the response of the protease to the drug. Because the variants 
used in this study were essentially selected at random, the techniques used here 
can be applied to larger panels of proteins and in other systems much like the 
techniques above for GRT. The specific machine learning techniques used in this 
study may have to be modified in order for the user to make the most logical 
interpretations of their data. Similarly, the interactions most perturbed between 
the protein and the inhibitor at the onset of mutations will also have to be 
identified and probed for different drugs and different systems. Still, the methods 
used in this thesis allow for the recognition that interpretation of virological 
outcome is just as necessary as its predictions in order to prevent resistance. 
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4.5. Using prior knowledge and current techniques to predict the 
onset of mutations to combat resistance
Throughout this thesis, the importance of studying various biochemical 
properties both statically and dynamically has been demonstrated. However, to 
capture the power of dynamics in its totality with respect to elucidating drug 
resistance, one must account for global patterns and trends within the target and 
how these patterns relate to drug resistance. Perhaps not all distal mutations 
play a direct role in drug resistance but their presence is necessary for viral 
replication otherwise that particular viral species would not be able to outcompete 
its counterparts. This in and of itself necessitates the need to understand why 
mutations far from the active site are present and how they contribute to 
resistance. 
In the process of structure based drug design, the methods used in this 
thesis to examine the roles of mutations outside of the active site can be 
subsequently incorporated after the “analyze structure of target and lead 
compound for interactions” step (Figure 4.1). Inclusion could consist of small time 
scale molecular dynamics simulations to monitor interactions in the identification 
of lead compounds, in addition to docking and other energy based design 
strategies. In chapter II, the MD simulations conducted were of a very short time 
scale but the wealth of information provided led to the network hypothesis where 
mutations are able to communicate global protein changes via hydrogen bonds. 
Without the use of dynamics this mechanism may have been overlooked.
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 These interactions can then be examined for perturbations by mutations 
founded through expert based rules or other means. The examination of 
structure networks within a target for the recognition of global communication 
patterns can be included in this analysis as well. In this regard, the full target 
network structure would need to be examined in the absence and presence of 
ligand to determine changes that occur throughout the protein when ligand is 
bound. In chapter III, we see that generally fixed (i.e. non-mutant) residues are 
used as “anchors” to communicate changes to the active site and flap regions of 
the protease (residues 5, 8, 9, 55, 83 etc) by examining the betweenness 
centrality, even in highly complex mutant backgrounds. A more in-depth analysis 
would reveal how the communication within each residue community changes 
between the proteases non-DRV and DRV bound states.  Understanding the 
global protease patterning and perturbations of global communication is useful 
for gaining insight into what mutations a new compound may trigger that are 
distal to the active site (Figure 4.2). 
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Figure 4.1 The process of structure-based drug design (SBDD) adapted from [117].  
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Figure 4.2 Modification to Figure 4.1 based on the findings presented in this thesis. 
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In chapter III, we also determine, from proteases of varied backgrounds, 
which specific mutations are most responsible for the changes in interactions 
necessary for DRV targeting. Knowing which mutations most heavily influence 
alterations in key interactions between a target and compound unlocks further 
implications behind the reason for the presence of mutations within and distal to 
the active site. For instance, determining that mutation I84V is going induce 
mutations at peripheral and distal sites such as 13, 32, 33 and 46 provides 
insight into why these mutations may have appeared in clinical trials with DRV. 
Previously, other groups have shown that non-active site mutations can appear 
before their active site counterparts to minimize the deleterious effects of active 
site mutations on viral replication [227]. DRV has been shown in multiple clinical 
trials to select for accessory mutations such as V32I and L33F without selecting 
for any active site mutations early on [186, 198]. Our findings substantiate that 
this inverse resistance mechanism may be employed by the protease against 
potent inhibitors such as DRV. Without the knowledge gained from our 
mutational studies, this information would not be confirmed. 
 In this work, we also looked at clinically derived variants and their 
resistance to DRV. Based on experts rules, DRV doesn’t necessarily select for all 
of the mutations we found to impede on its binding. This gives further insight into 
residues’ possible multiple roles in cross-resistance. Had this knowledge been 
implemented over the course of patient treatment to whichever approved inhibitor 
they were given at the time, a more informed decision could have been made for 
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their treatment optimization prior to accumulation of the many mutations seen. To 
aid clinicians and scientists in vigilance against drug resistance I propose that 
several steps be taken to comprehensively determine the best treatment options 
for patients. First, the collection of temporal resistance data must be acquired. 
This acquisition can be achieved in the laboratory such as those studies carried 
out by the scientists in the Swanstrom Lab at UNC-Chapel Hill from which we 
used several variants seen in chapter III. Or this acquisition could be attained 
from chronological patient sample collection and corresponding treatment history 
routinely and before treatment failure. Second, the dynamic interactions made 
between the target and inhibitor should be examined via molecular dynamics 
simulations and stored into a database. Finally, key interactions and their 
perturbations in the presence of mutations should be thoroughly investigated, 
including mutational impact on bonded and non-bonded interactions and the 
global networking of the protein. 
Much like the computer-aided GIS and TOS databases used for GRT to 
predict virological outcomes, taking the above steps could lead to the generation 
of computer-aided tools that would predict the onset mutations to an otherwise 
predictably successful inhibitor. Combining experimental knowledge and that 
information which was explored in this thesis; mechanisms employed in cross-
resistance, the interdependency of mutations within and away from the active 
site, and global communication patterns into a program could be complementary 
to the databases mentioned above. A program like this would be able to predict 
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likely mutations via the examination of interactions between protein and inhibitor 
and anticipate subsequent mutational patterns that may arise after the onset of 
mutations to a drug and allow for a more extensive prediction of treatment 
options that would best work for patients. 
4.6. Concluding Remarks
In conclusion, this thesis is an attempt to elucidate the interdependency of 
mutations distal to the active site of the HIV-1 protease and their direct role in 
drug resistance to protease inhibitor darunavir (DRV). We employed various 
techniques to examine the molecular dynamics simulations of selected protease 
variants complexed with DRV containing single site accessory mutations and 
more highly complex combinations of mutations. From these studies we have 
been able to determine that accessory mutations alone drive low levels of 
resistance to this potent inhibitor but they are able to alter the means by which 
DRV binds to the protease via the dynamic network of hydrogen bonds within the 
protease. In addition, we have been able to identify which mutations most perturb 
the interactions necessary for DRV to inhibit the protease. We were also able to 
elucidate from this panel of proteases, how the global interactions change 
throughout the protein in the presence of accessory mutations. Future directions 
for this work would be to examine this panel of variants using the methods in this 
thesis both in the absence of ligand and with substrates to gain insight into how 
the presence of mutations generally impacts dynamics. My hope is that this work 
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will aid in the improvement of inhibitor design in the future and provide a more 
complete assessment of treatment optimization in the clinic.
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